<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>LUCENTIS- ranibizumab injection, solution </strong><br>Genentech, Inc.<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">These highlights do not include all the information needed to use LUCENTIS safely and effectively. See full prescribing information for LUCENTIS.<br><br> LUCENTIS<span class="Sup">®</span> (ranibizumab injection)<br>Intravitreal Injection<br>Initial U.S. Approval:  2006</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>RECENT MAJOR CHANGES</span></h1>
<div><table class="Noautorules" width="100%">
<col align="left" valign="bottom" width="85%">
<col align="right" valign="bottom" width="15%">
<tbody class="Headless">
<tr>
<td align="left">Indications and Usage – <span class="product-label-link" type="condition" conceptid="4174977" conceptname="Diabetic retinopathy">Diabetic Retinopathy</span> in patients with <span class="product-label-link" type="condition" conceptid="380097" conceptname="Diabetic macular edema">Diabetic Macular Edema</span> (<a href="#S1.4">1.4</a>)</td>
<td align="right">2/2015</td>
</tr>
<tr>
<td align="left">Dosage and Administration – <span class="product-label-link" type="condition" conceptid="4174977" conceptname="Diabetic retinopathy">Diabetic Retinopathy</span> in patients with <span class="product-label-link" type="condition" conceptid="380097" conceptname="Diabetic macular edema">Diabetic Macular Edema</span> (<a href="#S2.5">2.5</a>)</td>
<td align="right">2/2015</td>
</tr>
<tr>
<td align="left">Warnings and Precautions (<a href="#S5.3">5.3</a>)</td>
<td align="right">2/2015</td>
</tr>
<tr>
<td align="left">Warnings and Precautions (<a href="#S5.4">5.4</a>)</td>
<td align="right">2/2015</td>
</tr>
</tbody>
</table></div>
</div>
<div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div>
<p class="Highlighta">LUCENTIS, a vascular endothelial growth factor (VEGF) inhibitor, is indicated for the treatment of patients with: </p>
<ul>
<li>Neovascular (Wet) Age-Related <span class="product-label-link" type="condition" conceptid="4083487" conceptname="Macular drusen">Macular Degeneration</span> (AMD) (<a href="#S1.1">1.1</a>)</li>
<li><span class="product-label-link" type="condition" conceptid="4290333" conceptname="Macular retinal edema">Macular Edema</span> Following <span class="product-label-link" type="condition" conceptid="313761" conceptname="Central retinal vein occlusion">Retinal Vein Occlusion</span> (RVO) (<a href="#S1.2">1.2</a>)</li>
<li><span class="product-label-link" type="condition" conceptid="380097" conceptname="Diabetic macular edema">Diabetic Macular Edema</span> (DME) (<a href="#S1.3">1.3</a>)</li>
<li><span class="product-label-link" type="condition" conceptid="4174977" conceptname="Diabetic retinopathy">Diabetic Retinopathy</span> in patients with DME (<a href="#S1.4">1.4</a>)</li>
</ul>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div>
<p class="Highlighta">For Ophthalmic Intravitreal Injection Only (<a href="#S2.1">2.1</a>)<br>  </p>
<p class="Highlighta"><span class="Bold">Neovascular (Wet) Age-Related <span class="product-label-link" type="condition" conceptid="4083487" conceptname="Macular drusen">Macular Degeneration</span> (AMD) (<a href="#S2.2">2.2</a>)</span> </p>
<p class="Highlighta">LUCENTIS 0.5 mg (0.05 mL) is recommended to be administered by intravitreal injection once a month (approximately 28 days).<br>  </p>
<p class="Highlighta">Although not as effective, patients may be treated with 3 monthly doses followed by less frequent dosing with regular assessment. </p>
<p class="Highlighta">Although not as effective, patients may also be treated with one dose every 3 months after 4 monthly doses.  Patients should be assessed regularly. </p>
<p class="Highlighta"><span class="Bold"><span class="product-label-link" type="condition" conceptid="4290333" conceptname="Macular retinal edema">Macular Edema</span> Following <span class="product-label-link" type="condition" conceptid="313761" conceptname="Central retinal vein occlusion">Retinal Vein Occlusion</span> (RVO) (<a href="#S2.3">2.3</a>)</span> </p>
<ul class="Disc"><li>LUCENTIS 0.5 mg (0.05 mL) is recommended to be administered by intravitreal injection once a month (approximately 28 days).</li></ul>
<p class="Highlighta"><span class="Bold"><span class="product-label-link" type="condition" conceptid="380097" conceptname="Diabetic macular edema">Diabetic Macular Edema</span> (DME) and <span class="product-label-link" type="condition" conceptid="4174977" conceptname="Diabetic retinopathy">Diabetic Retinopathy</span> (DR) in patients with <span class="product-label-link" type="condition" conceptid="380097" conceptname="Diabetic macular edema">Diabetic Macular Edema</span> (<a href="#S2.4">2.4</a>, <a href="#S2.5">2.5</a>)</span> </p>
<ul class="Disc"><li>LUCENTIS 0.3 mg (0.05 mL) is recommended to be administered by intravitreal injection once a month (approximately 28 days).</li></ul>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div>
<p class="Highlighta">Single-use glass vial designed to provide 0.05 mL for intravitreal injections: </p>
<ul class="Disc">
<li>10 mg/mL solution (LUCENTIS 0.5 mg) (<a href="#S3">3</a>)</li>
<li>6 mg/mL solution (LUCENTIS 0.3 mg) (<a href="#S3">3</a>)</li>
</ul>
</div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><ul>
<li>Ocular or periocular <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> (<a href="#S4.1">4.1</a>)</li>
<li><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span> (<a href="#S4.2">4.2</a>)</li>
</ul></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><ul>
<li><span class="product-label-link" type="condition" conceptid="438411" conceptname="Endophthalmitis">Endophthalmitis</span> and <span class="product-label-link" type="condition" conceptid="378414" conceptname="Retinal detachment">retinal detachments</span> may occur following intravitreal injections. Patients should be monitored following the injection (<a href="#S5.1">5.1</a>).</li>
<li>Increases in intraocular pressure (IOP) have been noted both pre- and post-intravitreal injection (<a href="#S5.2">5.2</a>).</li>
<li>There is a potential risk of arterial <span class="product-label-link" type="condition" conceptid="4185607" conceptname="Embolism">thromboembolic events</span> following intravitreal use of VEGF inhibitors (<a href="#S5.3">5.3</a>).</li>
<li>Fatal events occurred more frequently in patients with DME and DR at baseline, who were treated monthly with LUCENTIS compared with control (<a href="#S5.4">5.4</a>).</li>
</ul></div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<ul class="Disc"><li>The most common adverse reactions (reported more frequently in LUCENTIS-treated subjects than control subjects) are <span class="product-label-link" type="condition" conceptid="378756" conceptname="Conjunctival hemorrhage">conjunctival hemorrhage</span>, <span class="product-label-link" type="condition" conceptid="379031" conceptname="Pain in eye">eye pain</span>, <span class="product-label-link" type="condition" conceptid="4034681" conceptname="Vitreous floaters">vitreous floaters</span>, and increased IOP (<a href="#S6.2">6.2</a>).</li></ul>
<br><p class="Highlighta"><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact Genentech at 1-888-835-2555 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.</span> </p>
</div>
<div></div>
<div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
</div>
<div></div>
<div>
<div><div></div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
</div>
<div><div></div></div>
<div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div></div>
</div>
<div><div></div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION.</p>
<p class="HighlightsRevision">Revised: 2/2015</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc">1 INDICATIONS AND USAGE</a></h1>
<h2><a href="#section-1.1" class="toc">1.1	Neovascular (Wet) Age-Related <span class="product-label-link" type="condition" conceptid="4083487" conceptname="Macular drusen">Macular Degeneration</span> (AMD)</a></h2>
<h2><a href="#section-1.2" class="toc">1.2	<span class="product-label-link" type="condition" conceptid="4290333" conceptname="Macular retinal edema">Macular Edema</span> Following <span class="product-label-link" type="condition" conceptid="313761" conceptname="Central retinal vein occlusion">Retinal Vein Occlusion</span> (RVO)</a></h2>
<h2><a href="#section-1.3" class="toc">1.3	<span class="product-label-link" type="condition" conceptid="380097" conceptname="Diabetic macular edema">Diabetic Macular Edema</span> (DME)</a></h2>
<h2><a href="#section-1.4" class="toc"><span class="XmChange">1.4	<span class="product-label-link" type="condition" conceptid="4174977" conceptname="Diabetic retinopathy">Diabetic Retinopathy</span> (Non Proliferative <span class="product-label-link" type="condition" conceptid="4174977" conceptname="Diabetic retinopathy">Diabetic Retinopathy</span> (NPDR), Proliferative <span class="product-label-link" type="condition" conceptid="4174977" conceptname="Diabetic retinopathy">Diabetic Retinopathy</span> (PDR)) in patients with <span class="product-label-link" type="condition" conceptid="380097" conceptname="Diabetic macular edema">Diabetic Macular Edema</span> (DME)</span></a></h2>
<h1><a href="#section-2" class="toc">2	DOSAGE AND ADMINISTRATION</a></h1>
<h2><a href="#section-2.1" class="toc">2.1	General Dosing Information</a></h2>
<h2><a href="#section-2.2" class="toc">2.2	Neovascular (Wet) Age-Related <span class="product-label-link" type="condition" conceptid="4083487" conceptname="Macular drusen">Macular Degeneration</span> (AMD)</a></h2>
<h2><a href="#section-2.3" class="toc">2.3	<span class="product-label-link" type="condition" conceptid="4290333" conceptname="Macular retinal edema">Macular Edema</span> Following <span class="product-label-link" type="condition" conceptid="313761" conceptname="Central retinal vein occlusion">Retinal Vein Occlusion</span> (RVO)</a></h2>
<h2><a href="#section-2.4" class="toc">2.4	<span class="product-label-link" type="condition" conceptid="380097" conceptname="Diabetic macular edema">Diabetic Macular Edema</span> (DME)</a></h2>
<h2><a href="#section-2.5" class="toc"><span class="XmChange">2.5	<span class="product-label-link" type="condition" conceptid="4174977" conceptname="Diabetic retinopathy">Diabetic Retinopathy</span> in patients with <span class="product-label-link" type="condition" conceptid="380097" conceptname="Diabetic macular edema">Diabetic Macular Edema</span></span></a></h2>
<h2><a href="#section-2.6" class="toc">2.6	Preparation for Administration</a></h2>
<h2><a href="#section-2.7" class="toc">2.7	Administration</a></h2>
<h1><a href="#section-3" class="toc">3	DOSAGE FORMS AND STRENGTHS</a></h1>
<h1><a href="#section-4" class="toc">4	CONTRAINDICATIONS</a></h1>
<h2><a href="#section-4.1" class="toc">4.1	Ocular or Periocular <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span></a></h2>
<h2><a href="#section-4.2" class="toc">4.2	<span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span></a></h2>
<h1><a href="#section-5" class="toc">5	WARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-5.1" class="toc">5.1	<span class="product-label-link" type="condition" conceptid="438411" conceptname="Endophthalmitis">Endophthalmitis</span> and <span class="product-label-link" type="condition" conceptid="378414" conceptname="Retinal detachment">Retinal Detachments</span></a></h2>
<h2><a href="#section-5.2" class="toc">5.2	Increases in Intraocular Pressure</a></h2>
<h2><a href="#section-5.3" class="toc">5.3	<span class="product-label-link" type="condition" conceptid="4185607" conceptname="Embolism">Thromboembolic Events</span></a></h2>
<h2><a href="#section-5.4" class="toc"><span class="XmChange">5.4	Fatal Events in Patients with DME and DR at baseline</span></a></h2>
<h1><a href="#section-6" class="toc">6	ADVERSE REACTIONS</a></h1>
<h2><a href="#section-6.1" class="toc">6.1	Injection Procedure</a></h2>
<h2><a href="#section-6.2" class="toc">6.2	Clinical Studies Experience</a></h2>
<h2><a href="#section-6.3" class="toc">6.3	Immunogenicity</a></h2>
<h2><a href="#section-6.4" class="toc">6.4	Postmarketing Experience</a></h2>
<h1><a href="#section-7" class="toc">7	DRUG INTERACTIONS</a></h1>
<h1><a href="#section-8" class="toc">8	USE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-8.1" class="toc">8.1	Pregnancy</a></h2>
<h2><a href="#section-8.2" class="toc">8.3	Nursing Mothers</a></h2>
<h2><a href="#section-8.3" class="toc">8.4	Pediatric Use</a></h2>
<h2><a href="#section-8.4" class="toc">8.5	Geriatric Use</a></h2>
<h1><a href="#section-9" class="toc">10	OVERDOSAGE</a></h1>
<h1><a href="#section-10" class="toc">11	DESCRIPTION</a></h1>
<h1><a href="#section-11" class="toc">12	CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-11.1" class="toc">12.1	Mechanism of Action</a></h2>
<h2><a href="#section-11.2" class="toc">12.2	Pharmacodynamics</a></h2>
<h2><a href="#section-11.3" class="toc">12.3	Pharmacokinetics</a></h2>
<h1><a href="#section-12" class="toc">13	NONCLINICAL TOXICOLOGY</a></h1>
<h2><a href="#section-12.1" class="toc">13.1	Carcinogenesis, Mutagenesis, Impairment of Fertility</a></h2>
<h1><a href="#section-13" class="toc">14	CLINICAL STUDIES</a></h1>
<h2><a href="#section-13.1" class="toc">14.1	Neovascular (Wet) Age-Related <span class="product-label-link" type="condition" conceptid="4083487" conceptname="Macular drusen">Macular Degeneration</span> (AMD)</a></h2>
<h2><a href="#section-13.2" class="toc">14.2	<span class="product-label-link" type="condition" conceptid="4290333" conceptname="Macular retinal edema">Macular Edema</span> Following <span class="product-label-link" type="condition" conceptid="313761" conceptname="Central retinal vein occlusion">Retinal Vein Occlusion</span> (RVO)</a></h2>
<h2><a href="#section-13.3" class="toc">14.3	<span class="product-label-link" type="condition" conceptid="380097" conceptname="Diabetic macular edema">Diabetic Macular Edema</span> (DME)</a></h2>
<h2><a href="#section-13.4" class="toc">14.4	<span class="product-label-link" type="condition" conceptid="4174977" conceptname="Diabetic retinopathy">Diabetic Retinopathy</span> in patients with <span class="product-label-link" type="condition" conceptid="380097" conceptname="Diabetic macular edema">Diabetic Macular Edema</span> (DME)</a></h2>
<h1><a href="#section-14" class="toc">16	HOW SUPPLIED/STORAGE AND HANDLING</a></h1>
<h1><a href="#section-15" class="toc">17	PATIENT COUNSELING INFORMATION</a></h1>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="DLDE"></a><a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="S1"></a><a name="section-1"></a><p></p>
<h1>1 INDICATIONS AND USAGE</h1>
<p class="First">LUCENTIS is indicated for the treatment of patients with:</p>
<div class="Section" data-sectionCode="42229-5">
<a name="S1.1"></a><a name="section-1.1"></a><p></p>
<h2>1.1	Neovascular (Wet) Age-Related <span class="product-label-link" type="condition" conceptid="4083487" conceptname="Macular drusen">Macular Degeneration</span> (AMD)</h2>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S1.2"></a><a name="section-1.2"></a><p></p>
<h2>1.2	<span class="product-label-link" type="condition" conceptid="4290333" conceptname="Macular retinal edema">Macular Edema</span> Following <span class="product-label-link" type="condition" conceptid="313761" conceptname="Central retinal vein occlusion">Retinal Vein Occlusion</span> (RVO)</h2>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S1.3"></a><a name="section-1.3"></a><p></p>
<h2>1.3	<span class="product-label-link" type="condition" conceptid="380097" conceptname="Diabetic macular edema">Diabetic Macular Edema</span> (DME)</h2>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S1.4"></a><a name="section-1.4"></a><p></p>
<h2 style="border-left:1px solid;"><span class="XmChange">1.4	<span class="product-label-link" type="condition" conceptid="4174977" conceptname="Diabetic retinopathy">Diabetic Retinopathy</span> (Non Proliferative <span class="product-label-link" type="condition" conceptid="4174977" conceptname="Diabetic retinopathy">Diabetic Retinopathy</span> (NPDR), Proliferative <span class="product-label-link" type="condition" conceptid="4174977" conceptname="Diabetic retinopathy">Diabetic Retinopathy</span> (PDR)) in patients with <span class="product-label-link" type="condition" conceptid="380097" conceptname="Diabetic macular edema">Diabetic Macular Edema</span> (DME)</span></h2>
<p class="First"> </p>
</div>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="S2"></a><a name="section-2"></a><p></p>
<h1>2	DOSAGE AND ADMINISTRATION</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="S2.1"></a><a name="section-2.1"></a><p></p>
<h2>2.1	General Dosing Information</h2>
<p class="First">FOR OPHTHALMIC INTRAVITREAL INJECTION ONLY.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S2.2"></a><a name="section-2.2"></a><p></p>
<h2>2.2	Neovascular (Wet) Age-Related <span class="product-label-link" type="condition" conceptid="4083487" conceptname="Macular drusen">Macular Degeneration</span> (AMD)</h2>
<p class="First">LUCENTIS 0.5 mg (0.05 mL of 10 mg/mL LUCENTIS solution) is recommended to be administered by intravitreal injection once a month (approximately 28 days).</p>
<p>Although not as effective, patients may be treated with 3 monthly doses followed by less frequent dosing with regular assessment.  In the nine months after 3 initial monthly doses, less frequent dosing with 4-5 doses on average is expected to maintain visual acuity while monthly dosing may be expected to result in an additional average 1-2 letter gain.  Patients should be assessed regularly [<span class="Italics">see<a href="#S14.1"> Clinical Studies (14.1)</a></span>].</p>
<p>Although not as effective, patients may also be treated with one dose every 3 months after 4 monthly doses.  Compared with continued monthly dosing, dosing every 3 months over the next 9 months will lead to an approximate 5-letter (1-line) loss of visual acuity benefit, on average.  Patients should be assessed regularly [<span class="Italics">see<a href="#S14.1"> Clinical Studies (14.1)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S2.3"></a><a name="section-2.3"></a><p></p>
<h2>2.3	<span class="product-label-link" type="condition" conceptid="4290333" conceptname="Macular retinal edema">Macular Edema</span> Following <span class="product-label-link" type="condition" conceptid="313761" conceptname="Central retinal vein occlusion">Retinal Vein Occlusion</span> (RVO)</h2>
<p class="First">LUCENTIS 0.5 mg (0.05 mL of 10 mg/mL LUCENTIS solution) is recommended to be administered by intravitreal injection once a month (approximately 28 days).</p>
<p>In Studies RVO-1 and RVO-2, patients received monthly injections of LUCENTIS for 6 months. In spite of being guided by optical coherence tomography and visual acuity re-treatment criteria, patients who were then not treated at Month 6 experienced on average, a loss of visual acuity at Month 7, whereas patients who were treated at Month 6 did not. Patients should be treated monthly [<span class="Italics">see<a href="#S14.2"> Clinical Studies (14.2)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S2.4"></a><a name="section-2.4"></a><p></p>
<h2>2.4	<span class="product-label-link" type="condition" conceptid="380097" conceptname="Diabetic macular edema">Diabetic Macular Edema</span> (DME)</h2>
<p class="First">LUCENTIS 0.3 mg (0.05 mL of 6 mg/mL LUCENTIS solution) is recommended to be administered by intravitreal injection once a month (approximately 28 days).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S2.5"></a><a name="section-2.5"></a><p></p>
<h2 style="border-left:1px solid;"><span class="XmChange">2.5	<span class="product-label-link" type="condition" conceptid="4174977" conceptname="Diabetic retinopathy">Diabetic Retinopathy</span> in patients with <span class="product-label-link" type="condition" conceptid="380097" conceptname="Diabetic macular edema">Diabetic Macular Edema</span></span></h2>
<p class="First" style="border-left:1px solid;"><span class="XmChange">LUCENTIS 0.3 mg (0.05 mL of 6 mg/mL LUCENTIS solution) is recommended to be administered by intravitreal injection once a month (approximately 28 days).</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S2.6"></a><a name="section-2.6"></a><p></p>
<h2>2.6	Preparation for Administration</h2>
<p class="First">Using aseptic technique, all of the LUCENTIS vial contents are withdrawn through a 5-micron, 19-gauge filter needle attached to a 1-cc tuberculin syringe. The filter needle should be discarded after withdrawal of the vial contents and should not be used for intravitreal injection. The filter needle should be replaced with a sterile 30-gauge × 1/2-inch needle for the intravitreal injection. The contents should be expelled until the plunger tip is aligned with the line that marks 0.05 mL on the syringe.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S2.7"></a><a name="section-2.7"></a><p></p>
<h2>2.7	Administration</h2>
<p class="First">The intravitreal injection procedure should be carried out under controlled aseptic conditions, which include the use of sterile gloves, a sterile drape, and a sterile eyelid speculum (or equivalent). Adequate anesthesia and a broad-spectrum microbicide should be given prior to the injection.</p>
<p>Prior to and 30 minutes following the intravitreal injection, patients should be monitored for elevation in intraocular pressure using tonometry. Monitoring may also consist of a check for perfusion of the optic nerve head immediately after the injection [<span class="Italics">see<a href="#S5.2"> Warnings and Precautions (5.2)</a></span>]. Patients should also be monitored for and instructed to report any symptoms suggestive of <span class="product-label-link" type="condition" conceptid="438411" conceptname="Endophthalmitis">endophthalmitis</span> without delay following the injection [<span class="Italics">see<a href="#S5.1"> Warnings and Precautions (5.1)</a></span>].</p>
<p>Each vial should only be used for the treatment of a single eye. If the contralateral eye requires treatment, a new vial should be used and the sterile field, syringe, gloves, drapes, eyelid speculum, filter, and injection needles should be changed before LUCENTIS is administered to the other eye.</p>
<p>No special dosage modification is required for any of the populations that have been studied (e.g., gender, elderly).</p>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="S3"></a><a name="section-3"></a><p></p>
<h1>3	DOSAGE FORMS AND STRENGTHS</h1>
<p class="First">Single-use glass vial designed to provide 0.05 mL for intravitreal injection.</p>
<ul class="Disc">
<li>10 mg/mL solution (LUCENTIS 0.5 mg)</li>
<li>6 mg/mL solution (LUCENTIS 0.3 mg)</li>
</ul>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="S4"></a><a name="section-4"></a><p></p>
<h1>4	CONTRAINDICATIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="S4.1"></a><a name="section-4.1"></a><p></p>
<h2>4.1	Ocular or Periocular <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span></h2>
<p class="First">LUCENTIS is contraindicated in patients with ocular or periocular <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S4.2"></a><a name="section-4.2"></a><p></p>
<h2>4.2	<span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span></h2>
<p class="First">LUCENTIS is contraindicated in patients with known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to ranibizumab or any of the excipients in LUCENTIS. <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity reactions</span> may manifest as severe intraocular <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="S5"></a><a name="section-5"></a><p></p>
<h1>5	WARNINGS AND PRECAUTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.1"></a><a name="section-5.1"></a><p></p>
<h2>5.1	<span class="product-label-link" type="condition" conceptid="438411" conceptname="Endophthalmitis">Endophthalmitis</span> and <span class="product-label-link" type="condition" conceptid="378414" conceptname="Retinal detachment">Retinal Detachments</span></h2>
<p class="First">Intravitreal injections, including those with LUCENTIS, have been associated with <span class="product-label-link" type="condition" conceptid="438411" conceptname="Endophthalmitis">endophthalmitis</span> and <span class="product-label-link" type="condition" conceptid="378414" conceptname="Retinal detachment">retinal detachments</span>. Proper aseptic injection technique should always be used when administering LUCENTIS. In addition, patients should be monitored following the injection to permit early treatment should an <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> occur [<span class="Italics">see<a href="#S2.6"> Dosage and Administration (2.6</a>,<a href="#S2.7"> 2.7) </a>and<a href="#S17"> Patient Counseling Information (17)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.2"></a><a name="section-5.2"></a><p></p>
<h2>5.2	Increases in Intraocular Pressure</h2>
<p class="First">Increases in intraocular pressure have been noted both pre-injection and post-injection (at 60 minutes) while being treated with LUCENTIS. Monitor intraocular pressure prior to and following intravitreal injection with LUCENTIS and manage appropriately [<span class="Italics">see<a href="#S2.7"> Dosage and Administration (2.7)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.3"></a><a name="section-5.3"></a><p></p>
<h2>5.3	<span class="product-label-link" type="condition" conceptid="4185607" conceptname="Embolism">Thromboembolic Events</span></h2>
<p class="First">Although there was a low rate of arterial <span class="product-label-link" type="condition" conceptid="4185607" conceptname="Embolism">thromboembolic events</span> (ATEs) observed in the LUCENTIS clinical trials, there is a potential risk of ATEs following intravitreal use of VEGF inhibitors. ATEs are defined as nonfatal <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>, nonfatal <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>, or vascular <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> (including <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span> of unknown cause).</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-5.3.1"></a><p></p>
<p class="First"><span class="Italics">Neovascular (Wet) Age-Related <span class="product-label-link" type="condition" conceptid="4083487" conceptname="Macular drusen">Macular Degeneration</span></span></p>
<p>The ATE rate in the three controlled neovascular AMD studies (AMD-1, AMD-2, AMD-3) during the first year was 1.9% (17 of 874) in the combined group of patients treated with 0.3 mg or 0.5 mg LUCENTIS compared with 1.1% (5 of 441) in patients from the control arms [<span class="Italics">see <a href="#S14.1">Clinical Studies (14.1)</a></span>]. In the second year of Studies AMD-1 and AMD-2, the ATE rate was 2.6% (19 of 721) in the combined group of LUCENTIS-treated patients compared with 2.9% (10 of 344) in patients from the control arms.  In Study AMD-4, the ATE rates observed in the 0.5 mg arms during the first and second year were similar to rates observed in Studies AMD-1, AMD-2, and AMD-3.</p>
<p>In a pooled analysis of 2-year controlled studies (AMD-1, AMD-2, and a study of LUCENTIS used adjunctively with verteporfin photodynamic therapy), the <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> rate (including both ischemic and <span class="product-label-link" type="condition" conceptid="4046362" conceptname="Hemorrhagic cerebral infarction">hemorrhagic stroke</span>) was 2.7% (13 of 484) in patients treated with 0.5 mg LUCENTIS compared to 1.1% (5 of 435) in patients in the control arms (odds ratio 2.2 (95% confidence interval (0.8-7.1))).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-5.3.2"></a><p></p>
<p class="First"><span class="Italics"><span class="product-label-link" type="condition" conceptid="4290333" conceptname="Macular retinal edema">Macular Edema</span> Following <span class="product-label-link" type="condition" conceptid="313761" conceptname="Central retinal vein occlusion">Retinal Vein Occlusion</span></span></p>
<p>The ATE rate in the two controlled RVO studies during the first 6 months was 0.8% in both the LUCENTIS and control arms of the studies (4 of 525 in the combined group of patients treated with 0.3 mg or 0.5 mg LUCENTIS and 2 of 260 in the control arms) [<span class="Italics">see<a href="#S14.2"> Clinical Studies (14.2)</a></span>]. The <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> rate was 0.2% (1 of 525) in the combined group of LUCENTIS-treated patients compared to 0.4% (1 of 260) in the control arms.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-5.3.3"></a><p></p>
<p class="First" style="border-left:1px solid;"><span class="XmChange"><span class="Italics"><span class="product-label-link" type="condition" conceptid="380097" conceptname="Diabetic macular edema">Diabetic Macular Edema</span> and <span class="product-label-link" type="condition" conceptid="4174977" conceptname="Diabetic retinopathy">Diabetic Retinopathy</span></span></span></p>
<p style="border-left:1px solid;"><span class="XmChange">Safety data are derived from studies D-1 and D-2. All enrolled patients had DME and DR at baseline [<span class="Italics">see <a href="#S14.3">Clinical Studies (14.3</a>, <a href="#S14.4">14.4)</a></span>].</span></p>
<p style="border-left:1px solid;"><span class="XmChange">In a pooled analysis of Studies D-1 and D-2 [<span class="Italics">see <a href="#S14.3">Clinical Studies (14.3)</a></span>], the ATE rate at 2 years was 7.2% (18 of 250) with 0.5 mg LUCENTIS, 5.6% (14 of 250) with 0.3 mg LUCENTIS, and 5.2% (13 of 250) with control. The <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> rate at 2 years was 3.2% (8 of 250) with 0.5 mg LUCENTIS, 1.2% (3 of 250) with 0.3 mg LUCENTIS, and 1.6% (4 of 250) with control. At 3 years, the ATE rate was 10.4% (26 of 249) with 0.5 mg LUCENTIS and 10.8% (27 of 250) with 0.3 mg LUCENTIS; the <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> rate was 4.8% (12 of 249) with 0.5 mg LUCENTIS and 2.0% (5 of 250) with 0.3 mg LUCENTIS.</span></p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.4"></a><a name="section-5.4"></a><p></p>
<h2 style="border-left:1px solid;"><span class="XmChange">5.4	Fatal Events in Patients with DME and DR at baseline</span></h2>
<p class="First" style="border-left:1px solid;"><span class="XmChange"><span class="Italics"><span class="product-label-link" type="condition" conceptid="380097" conceptname="Diabetic macular edema">Diabetic Macular Edema</span> and <span class="product-label-link" type="condition" conceptid="4174977" conceptname="Diabetic retinopathy">Diabetic Retinopathy</span></span></span></p>
<p style="border-left:1px solid;"><span class="XmChange">Safety data are derived from studies D-1 and D-2. All enrolled patients had DME and DR at baseline [<span class="Italics">see <a href="#S14.3">Clinical Studies (14.3</a>, <a href="#S14.4">14.4)</a></span>].</span></p>
<p style="border-left:1px solid;"><span class="XmChange">A pooled analysis of Studies D-1 and D-2 [<span class="Italics">see<a href="#S14.3"> Clinical Studies (14.3)</a></span>], showed that fatalities in the first 2 years occurred in 4.4% (11 of 250) of patients treated with 0.5 mg LUCENTIS, in 2.8% (7 of 250) of patients treated with 0.3 mg LUCENTIS, and in 1.2% (3 of 250) of control patients. Over 3 years, fatalities occurred in 6.4% (16 of 249) of patients treated with 0.5 mg LUCENTIS and in 4.4% (11 of 250) of patients treated with 0.3 mg LUCENTIS. Although the rate of fatal events was low and included causes of <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> typical of patients with advanced diabetic complications, a potential relationship between these events and intravitreal use of VEGF inhibitors cannot be excluded.</span></p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="S6"></a><a name="section-6"></a><p></p>
<h1>6	ADVERSE REACTIONS</h1>
<p class="First">The following adverse reactions are discussed in greater detail in the <span class="Italics"><a href="#S5">Warnings and Precautions (5) </a></span>section of the label:</p>
<ul>
<li><span class="product-label-link" type="condition" conceptid="438411" conceptname="Endophthalmitis">Endophthalmitis</span> and <span class="product-label-link" type="condition" conceptid="378414" conceptname="Retinal detachment">Retinal Detachments</span></li>
<li>Increases in Intraocular Pressure</li>
<li><span class="product-label-link" type="condition" conceptid="4185607" conceptname="Embolism">Thromboembolic Events</span></li>
<li>Fatal Events in patients with DME and DR at baseline</li>
</ul>
<div class="Section" data-sectionCode="42229-5">
<a name="S6.1"></a><a name="section-6.1"></a><p></p>
<h2>6.1	Injection Procedure</h2>
<p class="First">Serious adverse reactions related to the injection procedure have occurred in &lt; 0.1% of intravitreal injections, including <span class="product-label-link" type="condition" conceptid="438411" conceptname="Endophthalmitis">endophthalmitis</span> [<span class="Italics">see<a href="#S5.1"> Warnings and Precautions (5.1)</a></span>], <span class="product-label-link" type="condition" conceptid="378414" conceptname="Retinal detachment">rhegmatogenous retinal detachment</span>, and iatrogenic <span class="product-label-link" type="condition" conceptid="374642" conceptname="Total traumatic cataract">traumatic cataract</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S6.2"></a><a name="section-6.2"></a><p></p>
<h2>6.2	Clinical Studies Experience</h2>
<p class="First">Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in one clinical trial of a drug cannot be directly compared with rates in the clinical trials of the same or another drug and may not reflect the rates observed in practice.</p>
<p>The data below reflect exposure to 0.5 mg LUCENTIS in 440 patients with neovascular AMD in Studies AMD-1, AMD-2, and AMD-3, and 259 patients with <span class="product-label-link" type="condition" conceptid="4290333" conceptname="Macular retinal edema">macular edema</span> following RVO.  The data also reflect exposure to 0.3 mg LUCENTIS in 250 patients with DME and DR at baseline [<span class="Italics">see<a href="#S14"> Clinical Studies (14)</a></span>].</p>
<p>Safety data observed in Study AMD-4 were consistent with these results.  On average, the rates and types of adverse reactions in patients were not significantly affected by dosing regimen.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.2.1"></a><p></p>
<p class="First"><span class="Italics">Ocular Reactions</span></p>
<p><a href="#table1">Table 1 </a>shows frequently reported ocular adverse reactions in LUCENTIS-treated patients compared with the control group.</p>
<a name="table1"></a><table width="100%">
<caption><span>Table 1 Ocular Reactions in the DME and DR, AMD, and RVO Studies</span></caption>
<col align="left" valign="middle" width="20%">
<col align="center" valign="middle" width="10%">
<col align="center" valign="middle" width="10%">
<col align="center" valign="middle" width="10%">
<col align="center" valign="middle" width="10%">
<col align="center" valign="middle" width="10%">
<col align="center" valign="middle" width="10%">
<col align="center" valign="middle" width="10%">
<col align="center" valign="middle" width="10%">
<thead>
<tr class="First">
<th class="Lrule Rrule" align="left"></th>
<th class="Botrule Rrule" align="center" colspan="2">DME and DR<br>2-year</th>
<th class="Botrule Rrule" align="center" colspan="2">AMD<br>2-year</th>
<th class="Botrule Rrule" align="center" colspan="2">AMD<br>1-year</th>
<th class="Botrule Rrule" align="center" colspan="2">RVO<br>6-month</th>
</tr>
<tr>
<th class="Lrule Rrule" align="center" rowspan="2">Adverse Reaction</th>
<th align="center">LUCENTIS<br>0.3 mg</th>
<th class="Rrule" align="center">Control</th>
<th align="center">LUCENTIS<br>0.5 mg</th>
<th class="Rrule" align="center">Control</th>
<th align="center">LUCENTIS<br>0.5 mg</th>
<th class="Rrule" align="center">Control</th>
<th align="center">LUCENTIS<br>0.5 mg</th>
<th class="Rrule" align="center">Control</th>
</tr>
<tr class="Last">
<th class="Botrule" align="center">n=250</th>
<th class="Botrule Rrule" align="center">n=250</th>
<th class="Botrule" align="center">n=379</th>
<th class="Botrule Rrule" align="center">n=379</th>
<th class="Botrule" align="center">n=440</th>
<th class="Botrule Rrule" align="center">n=441</th>
<th class="Botrule" align="center">n=259</th>
<th class="Botrule Rrule" align="center">n=260</th>
</tr>
</thead>
<tbody>
<tr class="First">
<td class="Botrule Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="378756" conceptname="Conjunctival hemorrhage">Conjunctival hemorrhage</span></td>
<td class="Botrule" align="center">47%</td>
<td class="Botrule Rrule" align="center">32%</td>
<td class="Botrule" align="center">74%</td>
<td class="Botrule Rrule" align="center">60%</td>
<td class="Botrule" align="center">64%</td>
<td class="Botrule Rrule" align="center">50%</td>
<td class="Botrule" align="center">48%</td>
<td class="Botrule Rrule" align="center">37%</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="379031" conceptname="Pain in eye">Eye pain</span></td>
<td class="Botrule" align="center">17%</td>
<td class="Botrule Rrule" align="center">13%</td>
<td class="Botrule" align="center">35%</td>
<td class="Botrule Rrule" align="center">30%</td>
<td class="Botrule" align="center">26%</td>
<td class="Botrule Rrule" align="center">20%</td>
<td class="Botrule" align="center">17%</td>
<td class="Botrule Rrule" align="center">12%</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4034681" conceptname="Vitreous floaters">Vitreous floaters</span></td>
<td class="Botrule" align="center">10%</td>
<td class="Botrule Rrule" align="center">4%</td>
<td class="Botrule" align="center">27%</td>
<td class="Botrule Rrule" align="center">8%</td>
<td class="Botrule" align="center">19%</td>
<td class="Botrule Rrule" align="center">5%</td>
<td class="Botrule" align="center">7%</td>
<td class="Botrule Rrule" align="center">2%</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4011560" conceptname="Raised intraocular pressure">Intraocular pressure increased</span></td>
<td class="Botrule" align="center">18%</td>
<td class="Botrule Rrule" align="center">7%</td>
<td class="Botrule" align="center">24%</td>
<td class="Botrule Rrule" align="center">7%</td>
<td class="Botrule" align="center">17%</td>
<td class="Botrule Rrule" align="center">5%</td>
<td class="Botrule" align="center">7%</td>
<td class="Botrule Rrule" align="center">2%</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4202518" conceptname="Vitreous detachment">Vitreous detachment</span></td>
<td class="Botrule" align="center">11%</td>
<td class="Botrule Rrule" align="center">15%</td>
<td class="Botrule" align="center">21%</td>
<td class="Botrule Rrule" align="center">19%</td>
<td class="Botrule" align="center">15%</td>
<td class="Botrule Rrule" align="center">15%</td>
<td class="Botrule" align="center">4%</td>
<td class="Botrule Rrule" align="center">2%</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left">Intraocular <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span></td>
<td class="Botrule" align="center">4%</td>
<td class="Botrule Rrule" align="center">3%</td>
<td class="Botrule" align="center">18%</td>
<td class="Botrule Rrule" align="center">8%</td>
<td class="Botrule" align="center">13%</td>
<td class="Botrule Rrule" align="center">7%</td>
<td class="Botrule" align="center">1%</td>
<td class="Botrule Rrule" align="center">3%</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="375545" conceptname="Cataract">Cataract</span></td>
<td class="Botrule" align="center">28%</td>
<td class="Botrule Rrule" align="center">32%</td>
<td class="Botrule" align="center">17%</td>
<td class="Botrule Rrule" align="center">14%</td>
<td class="Botrule" align="center">11%</td>
<td class="Botrule Rrule" align="center">9%</td>
<td class="Botrule" align="center">2%</td>
<td class="Botrule Rrule" align="center">2%</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left">Foreign body sensation in eyes</td>
<td class="Botrule" align="center">10%</td>
<td class="Botrule Rrule" align="center">5%</td>
<td class="Botrule" align="center">16%</td>
<td class="Botrule Rrule" align="center">14%</td>
<td class="Botrule" align="center">13%</td>
<td class="Botrule Rrule" align="center">10%</td>
<td class="Botrule" align="center">7%</td>
<td class="Botrule Rrule" align="center">5%</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4049206" conceptname="Burning sensation in eye">Eye irritation</span></td>
<td class="Botrule" align="center">8%</td>
<td class="Botrule Rrule" align="center">5%</td>
<td class="Botrule" align="center">15%</td>
<td class="Botrule Rrule" align="center">15%</td>
<td class="Botrule" align="center">13%</td>
<td class="Botrule Rrule" align="center">12%</td>
<td class="Botrule" align="center">7%</td>
<td class="Botrule Rrule" align="center">6%</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="435553" conceptname="Epiphora">Lacrimation increased</span></td>
<td class="Botrule" align="center">5%</td>
<td class="Botrule Rrule" align="center">4%</td>
<td class="Botrule" align="center">14%</td>
<td class="Botrule Rrule" align="center">12%</td>
<td class="Botrule" align="center">8%</td>
<td class="Botrule Rrule" align="center">8%</td>
<td class="Botrule" align="center">2%</td>
<td class="Botrule Rrule" align="center">3%</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="378425" conceptname="Blepharitis">Blepharitis</span></td>
<td class="Botrule" align="center">3%</td>
<td class="Botrule Rrule" align="center">2%</td>
<td class="Botrule" align="center">12%</td>
<td class="Botrule Rrule" align="center">8%</td>
<td class="Botrule" align="center">8%</td>
<td class="Botrule Rrule" align="center">5%</td>
<td class="Botrule" align="center">0%</td>
<td class="Botrule Rrule" align="center">1%</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="373204" conceptname="Conjunctival xerosis">Dry eye</span></td>
<td class="Botrule" align="center">5%</td>
<td class="Botrule Rrule" align="center">3%</td>
<td class="Botrule" align="center">12%</td>
<td class="Botrule Rrule" align="center">7%</td>
<td class="Botrule" align="center">7%</td>
<td class="Botrule Rrule" align="center">7%</td>
<td class="Botrule" align="center">3%</td>
<td class="Botrule Rrule" align="center">3%</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="374034" conceptname="Visual disturbance">Visual disturbance</span> or <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">vision blurred</span></td>
<td class="Botrule" align="center">8%</td>
<td class="Botrule Rrule" align="center">4%</td>
<td class="Botrule" align="center">18%</td>
<td class="Botrule Rrule" align="center">15%</td>
<td class="Botrule" align="center">13%</td>
<td class="Botrule Rrule" align="center">10%</td>
<td class="Botrule" align="center">5%</td>
<td class="Botrule Rrule" align="center">3%</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left">Eye pruritis</td>
<td class="Botrule" align="center">4%</td>
<td class="Botrule Rrule" align="center">4%</td>
<td class="Botrule" align="center">12%</td>
<td class="Botrule Rrule" align="center">11%</td>
<td class="Botrule" align="center">9%</td>
<td class="Botrule Rrule" align="center">7%</td>
<td class="Botrule" align="center">1%</td>
<td class="Botrule Rrule" align="center">2%</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="442546" conceptname="Red eye">Ocular hyperemia</span></td>
<td class="Botrule" align="center">9%</td>
<td class="Botrule Rrule" align="center">9%</td>
<td class="Botrule" align="center">11%</td>
<td class="Botrule Rrule" align="center">8%</td>
<td class="Botrule" align="center">7%</td>
<td class="Botrule Rrule" align="center">4%</td>
<td class="Botrule" align="center">5%</td>
<td class="Botrule Rrule" align="center">3%</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="378416" conceptname="Retinal disorder">Retinal disorder</span></td>
<td class="Botrule" align="center">2%</td>
<td class="Botrule Rrule" align="center">2%</td>
<td class="Botrule" align="center">10%</td>
<td class="Botrule Rrule" align="center">7%</td>
<td class="Botrule" align="center">8%</td>
<td class="Botrule Rrule" align="center">4%</td>
<td class="Botrule" align="center">2%</td>
<td class="Botrule Rrule" align="center">1%</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4208223" conceptname="Disorder of macula of retina">Maculopathy</span></td>
<td class="Botrule" align="center">5%</td>
<td class="Botrule Rrule" align="center">7%</td>
<td class="Botrule" align="center">9%</td>
<td class="Botrule Rrule" align="center">9%</td>
<td class="Botrule" align="center">6%</td>
<td class="Botrule Rrule" align="center">6%</td>
<td class="Botrule" align="center">11%</td>
<td class="Botrule Rrule" align="center">7%</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4090255" conceptname="Retinal drusen">Retinal degeneration</span></td>
<td class="Botrule" align="center">1%</td>
<td class="Botrule Rrule" align="center">0%</td>
<td class="Botrule" align="center">8%</td>
<td class="Botrule Rrule" align="center">6%</td>
<td class="Botrule" align="center">5%</td>
<td class="Botrule Rrule" align="center">3%</td>
<td class="Botrule" align="center">1%</td>
<td class="Botrule Rrule" align="center">0%</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="372912" conceptname="Visual discomfort">Ocular discomfort</span></td>
<td class="Botrule" align="center">2%</td>
<td class="Botrule Rrule" align="center">1%</td>
<td class="Botrule" align="center">7%</td>
<td class="Botrule Rrule" align="center">4%</td>
<td class="Botrule" align="center">5%</td>
<td class="Botrule Rrule" align="center">2%</td>
<td class="Botrule" align="center">2%</td>
<td class="Botrule Rrule" align="center">2%</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="377283" conceptname="Conjunctival hyperemia">Conjunctival hyperemia</span></td>
<td class="Botrule" align="center">1%</td>
<td class="Botrule Rrule" align="center">2%</td>
<td class="Botrule" align="center">7%</td>
<td class="Botrule Rrule" align="center">6%</td>
<td class="Botrule" align="center">5%</td>
<td class="Botrule Rrule" align="center">4%</td>
<td class="Botrule" align="center">0%</td>
<td class="Botrule Rrule" align="center">0%</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4132632" conceptname="Posterior capsule opacification">Posterior capsule opacification</span></td>
<td class="Botrule" align="center">4%</td>
<td class="Botrule Rrule" align="center">3%</td>
<td class="Botrule" align="center">7%</td>
<td class="Botrule Rrule" align="center">4%</td>
<td class="Botrule" align="center">2%</td>
<td class="Botrule Rrule" align="center">2%</td>
<td class="Botrule" align="center">0%</td>
<td class="Botrule Rrule" align="center">1%</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4316205" conceptname="Injection site hemorrhage">Injection site hemorrhage</span></td>
<td class="Botrule" align="center">1%</td>
<td class="Botrule Rrule" align="center">0%</td>
<td class="Botrule" align="center">5%</td>
<td class="Botrule Rrule" align="center">2%</td>
<td class="Botrule" align="center">3%</td>
<td class="Botrule Rrule" align="center">1%</td>
<td class="Botrule" align="center">0%</td>
<td class="Botrule Rrule" align="center">0%</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.2.2"></a><p></p>
<p class="First"><span class="Italics">Non-Ocular Reactions</span></p>
<p>Non-ocular adverse reactions with an incidence of ≥ 5% in patients receiving LUCENTIS for DR, DME, AMD, and/or RVO and which occurred at a ≥ 1% higher frequency in patients treated with LUCENTIS compared to control are shown in<a href="#table2"> Table 2</a>. Though less common, <span class="product-label-link" type="condition" conceptid="4029919" conceptname="Wound">wound</span> healing complications were also observed in some studies.</p>
<a name="table2"></a><table width="100%">
<caption><span>Table 2 Non-Ocular Reactions in the DME and DR, AMD and RVO Studies</span></caption>
<col align="left" valign="middle" width="20%">
<col align="center" valign="middle" width="10%">
<col align="center" valign="middle" width="10%">
<col align="center" valign="middle" width="10%">
<col align="center" valign="middle" width="10%">
<col align="center" valign="middle" width="10%">
<col align="center" valign="middle" width="10%">
<col align="center" valign="middle" width="10%">
<col align="center" valign="middle" width="10%">
<thead>
<tr class="First">
<th class="Lrule Rrule" align="left"></th>
<th class="Botrule Rrule" align="center" colspan="2">DME and DR<br>2-year</th>
<th class="Botrule Rrule" align="center" colspan="2">AMD<br>2-year</th>
<th class="Botrule Rrule" align="center" colspan="2">AMD<br>1-year</th>
<th class="Botrule Rrule" align="center" colspan="2">RVO<br>6-month</th>
</tr>
<tr>
<th class="Lrule Rrule" align="center" rowspan="2">Adverse Reaction</th>
<th align="center">LUCENTIS<br>0.3 mg</th>
<th class="Rrule" align="center">Control</th>
<th align="center">LUCENTIS<br>0.5 mg</th>
<th class="Rrule" align="center">Control</th>
<th align="center">LUCENTIS<br>0.5 mg</th>
<th class="Rrule" align="center">Control</th>
<th align="center">LUCENTIS<br>0.5 mg</th>
<th class="Rrule" align="center">Control</th>
</tr>
<tr class="Botrule Last">
<th align="center">n=250</th>
<th class="Rrule" align="center">n=250</th>
<th align="center">n=379</th>
<th class="Rrule" align="center">n=379</th>
<th align="center">n=440</th>
<th class="Rrule" align="center">n=441</th>
<th align="center">n=259</th>
<th class="Rrule" align="center">n=260</th>
</tr>
</thead>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4197268" conceptname="Nasopharyngitis">Nasopharyngitis</span></td>
<td align="center">12%</td>
<td class="Rrule" align="center">6%</td>
<td align="center">16%</td>
<td class="Rrule" align="center">13%</td>
<td align="center">8%</td>
<td class="Rrule" align="center">9%</td>
<td align="center">5%</td>
<td class="Rrule" align="center">4%</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">Anemia</span></td>
<td align="center">11%</td>
<td class="Rrule" align="center">10%</td>
<td align="center">8%</td>
<td class="Rrule" align="center">7%</td>
<td align="center">4%</td>
<td class="Rrule" align="center">3%</td>
<td align="center">1%</td>
<td class="Rrule" align="center">1%</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></td>
<td align="center">10%</td>
<td class="Rrule" align="center">9%</td>
<td align="center">9%</td>
<td class="Rrule" align="center">6%</td>
<td align="center">5%</td>
<td class="Rrule" align="center">5%</td>
<td align="center">1%</td>
<td class="Rrule" align="center">2%</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">Cough</span></td>
<td align="center">9%</td>
<td class="Rrule" align="center">4%</td>
<td align="center">9%</td>
<td class="Rrule" align="center">8%</td>
<td align="center">5%</td>
<td class="Rrule" align="center">4%</td>
<td align="center">1%</td>
<td class="Rrule" align="center">2%</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">Constipation</span></td>
<td align="center">8%</td>
<td class="Rrule" align="center">4%</td>
<td align="center">5%</td>
<td class="Rrule" align="center">7%</td>
<td align="center">3%</td>
<td class="Rrule" align="center">4%</td>
<td align="center">0%</td>
<td class="Rrule" align="center">1%</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="40478941" conceptname="Seasonal allergy">Seasonal allergy</span></td>
<td align="center">8%</td>
<td class="Rrule" align="center">4%</td>
<td align="center">4%</td>
<td class="Rrule" align="center">4%</td>
<td align="center">2%</td>
<td class="Rrule" align="center">2%</td>
<td align="center">0%</td>
<td class="Rrule" align="center">2%</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="437827" conceptname="Pure hypercholesterolemia">Hypercholesterolemia</span></td>
<td align="center">7%</td>
<td class="Rrule" align="center">5%</td>
<td align="center">5%</td>
<td class="Rrule" align="center">5%</td>
<td align="center">3%</td>
<td class="Rrule" align="center">2%</td>
<td align="center">1%</td>
<td class="Rrule" align="center">1%</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4266367" conceptname="Influenza">Influenza</span></td>
<td align="center">7%</td>
<td class="Rrule" align="center">3%</td>
<td align="center">7%</td>
<td class="Rrule" align="center">5%</td>
<td align="center">3%</td>
<td class="Rrule" align="center">2%</td>
<td align="center">3%</td>
<td class="Rrule" align="center">2%</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">Renal failure</span></td>
<td align="center">7%</td>
<td class="Rrule" align="center">6%</td>
<td align="center">1%</td>
<td class="Rrule" align="center">1%</td>
<td align="center">0%</td>
<td class="Rrule" align="center">0%</td>
<td align="center">0%</td>
<td class="Rrule" align="center">0%</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4181583" conceptname="Upper respiratory infection">Upper respiratory tract infection</span></td>
<td align="center">7%</td>
<td class="Rrule" align="center">7%</td>
<td align="center">9%</td>
<td class="Rrule" align="center">8%</td>
<td align="center">5%</td>
<td class="Rrule" align="center">5%</td>
<td align="center">2%</td>
<td class="Rrule" align="center">2%</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">Gastroesophageal reflux disease</span></td>
<td align="center">6%</td>
<td class="Rrule" align="center">4%</td>
<td align="center">4%</td>
<td class="Rrule" align="center">6%</td>
<td align="center">3%</td>
<td class="Rrule" align="center">4%</td>
<td align="center">1%</td>
<td class="Rrule" align="center">0%</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></td>
<td align="center">6%</td>
<td class="Rrule" align="center">8%</td>
<td align="center">12%</td>
<td class="Rrule" align="center">9%</td>
<td align="center">6%</td>
<td class="Rrule" align="center">5%</td>
<td align="center">3%</td>
<td class="Rrule" align="center">3%</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4094513" conceptname="Ankle edema">Edema peripheral</span></td>
<td align="center">6%</td>
<td class="Rrule" align="center">4%</td>
<td align="center">3%</td>
<td class="Rrule" align="center">5%</td>
<td align="center">2%</td>
<td class="Rrule" align="center">3%</td>
<td align="center">0%</td>
<td class="Rrule" align="center">1%</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="198185" conceptname="Chronic renal failure">Renal failure chronic</span></td>
<td align="center">6%</td>
<td class="Rrule" align="center">2%</td>
<td align="center">0%</td>
<td class="Rrule" align="center">1%</td>
<td align="center">0%</td>
<td class="Rrule" align="center">0%</td>
<td align="center">0%</td>
<td class="Rrule" align="center">0%</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">Neuropathy peripheral</span></td>
<td align="center">5%</td>
<td class="Rrule" align="center">3%</td>
<td align="center">1%</td>
<td class="Rrule" align="center">1%</td>
<td align="center">1%</td>
<td class="Rrule" align="center">0%</td>
<td align="center">0%</td>
<td class="Rrule" align="center">0%</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4283893" conceptname="Sinusitis">Sinusitis</span></td>
<td align="center">5%</td>
<td class="Rrule" align="center">8%</td>
<td align="center">8%</td>
<td class="Rrule" align="center">7%</td>
<td align="center">5%</td>
<td class="Rrule" align="center">5%</td>
<td align="center">3%</td>
<td class="Rrule" align="center">2%</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="256451" conceptname="Bronchitis">Bronchitis</span></td>
<td align="center">4%</td>
<td class="Rrule" align="center">4%</td>
<td align="center">11%</td>
<td class="Rrule" align="center">9%</td>
<td align="center">6%</td>
<td class="Rrule" align="center">5%</td>
<td align="center">0%</td>
<td class="Rrule" align="center">2%</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="313217" conceptname="Atrial fibrillation">Atrial fibrillation</span></td>
<td align="center">3%</td>
<td class="Rrule" align="center">3%</td>
<td align="center">5%</td>
<td class="Rrule" align="center">4%</td>
<td align="center">2%</td>
<td class="Rrule" align="center">2%</td>
<td align="center">1%</td>
<td class="Rrule" align="center">0%</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">Arthralgia</span></td>
<td align="center">3%</td>
<td class="Rrule" align="center">3%</td>
<td align="center">11%</td>
<td class="Rrule" align="center">9%</td>
<td align="center">5%</td>
<td class="Rrule" align="center">5%</td>
<td align="center">2%</td>
<td class="Rrule" align="center">1%</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="255573" conceptname="Chronic obstructive lung disease">Chronic obstructive pulmonary disease</span></td>
<td align="center">1%</td>
<td class="Rrule" align="center">1%</td>
<td align="center">6%</td>
<td class="Rrule" align="center">3%</td>
<td align="center">3%</td>
<td class="Rrule" align="center">1%</td>
<td align="center">0%</td>
<td class="Rrule" align="center">0%</td>
</tr>
<tr class="Botrule Last">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4029919" conceptname="Wound">Wound</span> healing complications</td>
<td align="center">1%</td>
<td class="Rrule" align="center">0%</td>
<td align="center">1%</td>
<td class="Rrule" align="center">1%</td>
<td align="center">1%</td>
<td class="Rrule" align="center">0%</td>
<td align="center">0%</td>
<td class="Rrule" align="center">0%</td>
</tr>
</tbody>
</table>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S6.3"></a><a name="section-6.3"></a><p></p>
<h2>6.3	Immunogenicity</h2>
<p class="First">As with all therapeutic proteins, there is the potential for an immune response in patients treated with LUCENTIS. The immunogenicity data reflect the percentage of patients whose test results were considered positive for antibodies to LUCENTIS in immunoassays and are highly dependent on the sensitivity and specificity of the assays.</p>
<p>The pre-treatment incidence of immunoreactivity to LUCENTIS was 0%-5% across treatment groups. After monthly dosing with LUCENTIS for 6 to 24 months, antibodies to LUCENTIS were detected in approximately 1%-9% of patients.</p>
<p>The clinical significance of immunoreactivity to LUCENTIS is unclear at this time. Among neovascular AMD patients with the highest levels of immunoreactivity, some were noted to have <span class="product-label-link" type="condition" conceptid="4274964" conceptname="Iritis">iritis</span> or <span class="product-label-link" type="condition" conceptid="4317991" conceptname="Vitritis">vitritis</span>. Intraocular <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span> was not observed in DME and DR at baseline, or RVO patients with the highest levels of immunoreactivity.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S6.4"></a><a name="section-6.4"></a><p></p>
<h2>6.4	Postmarketing Experience</h2>
<p class="First">The following adverse reactions have been identified during post-approval use of LUCENTIS. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.</p>
<ul class="Disc"><li>Ocular: Tear of retinal pigment epithelium among patients with neovascular AMD</li></ul>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="S7"></a><a name="section-7"></a><p></p>
<h1>7	DRUG INTERACTIONS</h1>
<p class="First">Drug interaction studies have not been conducted with LUCENTIS.</p>
<p>LUCENTIS intravitreal injection has been used adjunctively with verteporfin photodynamic therapy (PDT). Twelve (12) of 105 (11%) patients with neovascular AMD developed serious intraocular <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span>; in 10 of the 12 patients, this occurred when LUCENTIS was administered 7 days (± 2 days) after verteporfin PDT.</p>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="S8"></a><a name="section-8"></a><p></p>
<h1>8	USE IN SPECIFIC POPULATIONS</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="S8.1"></a><a name="section-8.1"></a><p></p>
<h2>8.1	Pregnancy</h2>
<div class="Section" data-sectionCode="34077-8">
<a name="section-8.1.1"></a><p></p>
<p class="First">There are no studies of LUCENTIS in pregnant women. An embryo-fetal developmental toxicity study was performed on pregnant cynomolgus monkeys. Pregnant animals received intravitreal injections of ranibizumab every 14 days starting on Day 20  of gestation, until Day 62 at doses of 0, 0.125, and 1 mg/eye. Skeletal abnormalities including incomplete and/or irregular ossification of bones in the skull, vertebral column, and hindlimbs and shortened supernumerary ribs were seen at a low incidence in fetuses from animals treated with 1 mg/eye of ranibizumab.  The 1 mg/eye dose resulted in trough serum ranibizumab levels up to 13 times higher than predicted C<span class="Sub">max</span> levels with single eye treatment in humans. No skeletal abnormalities were seen at the lower dose of 0.125 mg/eye, a dose which resulted in trough exposures equivalent to single eye treatment in humans.  No effect on the weight or structure of the placenta, maternal toxicity, or embryotoxicity was observed. </p>
<p>Animal reproduction studies are not always predictive of human response. It is also not known whether ranibizumab can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Based on the anti-VEGF mechanism of action for ranibizumab [<span class="Italics">see<a href="#S12.1"> Clinical Pharmacology (12.1)</a></span>], treatment with LUCENTIS may pose a risk to embryo-fetal development (including <span class="product-label-link" type="condition" conceptid="4240324" conceptname="Teratogenesis">teratogenicity</span>) and reproductive capacity. LUCENTIS should be given to a pregnant woman only if clearly needed.</p>
</div>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="S8.3"></a><a name="section-8.2"></a><p></p>
<h2>8.3	Nursing Mothers</h2>
<p class="First">It is not known whether ranibizumab is excreted in human milk. Because many drugs are excreted in human milk, and because the potential for absorption and harm to infant growth and development exists, caution should be exercised when LUCENTIS is administered to a nursing woman.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="S8.4"></a><a name="section-8.3"></a><p></p>
<h2>8.4	Pediatric Use</h2>
<p class="First">The safety and effectiveness of LUCENTIS in pediatric patients have not been established.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="S8.5"></a><a name="section-8.4"></a><p></p>
<h2>8.5	Geriatric Use</h2>
<p class="First">In the clinical studies, approximately 79% (2387 of 3005) of patients randomized to treatment with LUCENTIS were ≥ 65 years of age and approximately 54% (1636 of 3005) were ≥ 75 years of age [<span class="Italics">see<a href="#S14"> Clinical Studies (14)</a></span>]. No notable differences in efficacy or safety were seen with increasing age in these studies.  Age did not have a significant effect on systemic exposure.</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="S10"></a><a name="section-9"></a><p></p>
<h1>10	OVERDOSAGE</h1>
<p class="First">More concentrated doses as high as 2 mg ranibizumab in 0.05 mL have been administered to patients. No additional unexpected adverse reactions were seen.</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="S11"></a><a name="section-10"></a><p></p>
<h1>11	DESCRIPTION</h1>
<p class="First">LUCENTIS<span class="Sup">®</span> (ranibizumab injection) is a recombinant humanized IgG1 kappa isotype monoclonal antibody fragment designed for intraocular use. Ranibizumab binds to and inhibits the biologic activity of human vascular endothelial growth factor A (VEGF-A). Ranibizumab, which lacks an Fc region, has a molecular weight of approximately 48 kilodaltons and is produced by an <span class="Italics">E. coli</span> expression system in a nutrient medium containing the antibiotic tetracycline. Tetracycline is not detectable in the final product.</p>
<p>LUCENTIS is a sterile, colorless to <span class="product-label-link" type="condition" conceptid="4260836" conceptname="Blanching of skin">pale</span> yellow solution in a single-use glass vial. LUCENTIS is supplied as a preservative-free, sterile solution in a single-use glass vial designed to deliver 0.05 mL of 10 mg/mL LUCENTIS (0.5 mg dose vial) or 6 mg/mL LUCENTIS (0.3 mg dose vial) aqueous solution with 10 mM histidine HCl, 10% α,α-trehalose dihydrate, 0.01% polysorbate 20, pH 5.5.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="S12"></a><a name="section-11"></a><p></p>
<h1>12	CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="S12.1"></a><a name="section-11.1"></a><p></p>
<h2>12.1	Mechanism of Action</h2>
<p class="First">Ranibizumab binds to the receptor binding site of active forms of VEGF-A, including the biologically active, cleaved form of this molecule, VEGF<span class="Sub">110</span>. VEGF-A has been shown to cause <span class="product-label-link" type="condition" conceptid="4045406" conceptname="Neovascularization">neovascularization</span> and leakage in models of ocular angiogenesis and <span class="product-label-link" type="condition" conceptid="4093906" conceptname="Obstruction">vascular occlusion</span> and is thought to contribute to pathophysiology of neovascular AMD, <span class="product-label-link" type="condition" conceptid="4290333" conceptname="Macular retinal edema">macular edema</span> following RVO, DR and DME. The binding of ranibizumab to VEGF-A prevents the interaction of VEGF-A with its receptors (VEGFR1 and VEGFR2) on the surface of endothelial cells, reducing endothelial cell proliferation, vascular leakage, and new blood vessel formation.</p>
</div>
<div class="Section" data-sectionCode="43681-6">
<a name="S12.2"></a><a name="section-11.2"></a><p></p>
<h2>12.2	Pharmacodynamics</h2>
<p class="First">Increased retinal thickness (i.e., center point thickness (CPT) or central foveal thickness (CFT)), as assessed by optical coherence tomography (OCT) is associated with neovascular AMD, <span class="product-label-link" type="condition" conceptid="4290333" conceptname="Macular retinal edema">macular edema</span> following RVO, and DME. Leakage from choroidal <span class="product-label-link" type="condition" conceptid="4045406" conceptname="Neovascularization">neovascularization</span> (CNV) as assessed by fluorescein angiography (FA) is associated with neovascular AMD. Microvascular retinal changes and <span class="product-label-link" type="condition" conceptid="4045406" conceptname="Neovascularization">neovascularization</span>, as assessed by color fundus photography, are associated with <span class="product-label-link" type="condition" conceptid="4174977" conceptname="Diabetic retinopathy">diabetic retinopathy</span>.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.2.1"></a><p></p>
<p class="First"><span class="Italics">Neovascular (Wet) Age-Related <span class="product-label-link" type="condition" conceptid="4083487" conceptname="Macular drusen">Macular Degeneration</span></span></p>
<p>In Study AMD-3, CPT was assessed by time domain (TD)-OCT in 118 of 184 patients. TD-OCT measurements were collected at baseline, Months 1, 2, 3, 5, 8, and 12. In patients treated with LUCENTIS, CPT decreased, on average, more than in the sham group from baseline through Month 12. CPT decreased by Month 1 and decreased further at Month 3, on average. In this study, CPT data did not provide information useful in influencing treatment decisions [<span class="Italics">see<a href="#S14.1"> Clinical Studies (14.1)</a></span>].</p>
<p>In Study AMD-4, CFT was assessed by spectral domain (SD)-OCT in all patients; on average, CFT reductions were observed beginning at Day 7 following the first LUCENTIS injection through Month 24.  CFT data did not provide information capable of predicting final visual acuity results [see<span class="Italics"><a href="#S14.1"> Clinical Studies (14.1)</a></span>].</p>
<p>In patients treated with LUCENTIS, the area of CNV leakage, on average, decreased by Month 3 as assessed by FA. The area of CNV leakage for an individual patient was not correlated with visual acuity.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.2.2"></a><p></p>
<p class="First"><span class="Italics"><span class="product-label-link" type="condition" conceptid="4290333" conceptname="Macular retinal edema">Macular Edema</span> Following <span class="product-label-link" type="condition" conceptid="313761" conceptname="Central retinal vein occlusion">Retinal Vein Occlusion</span> </span></p>
<p>On average, CPT reductions were observed in Studies RVO-1 and RVO-2 beginning at Day 7 following the first LUCENTIS injection through Month 6. CPT was not evaluated as a means to guide treatment decisions [<span class="Italics">see<a href="#S14.2"> Clinical Studies (14.2)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.2.3"></a><p></p>
<p class="First"><span class="Italics"><span class="product-label-link" type="condition" conceptid="380097" conceptname="Diabetic macular edema">Diabetic Macular Edema</span></span></p>
<p>On average, CPT reductions were observed in Studies DME-1 and DME-2 beginning at Day 7 following the first LUCENTIS injection through Month 36. CPT data did not provide information useful in influencing treatment decisions [<span class="Italics">see<a href="#S14.3"> Clinical Studies (14.3)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.2.4"></a><p></p>
<p class="First"><span class="Italics"><span class="product-label-link" type="condition" conceptid="4174977" conceptname="Diabetic retinopathy">Diabetic Retinopathy</span> in patients with <span class="product-label-link" type="condition" conceptid="380097" conceptname="Diabetic macular edema">Diabetic Macular Edema</span></span></p>
<p>Improvements from baseline in DR severity as assessed on fundus photography were observed in Studies D-1 and D-2 at Month 3 (first scheduled DR photographic assessment after randomization) through Month 36 [<span class="Italics">see<a href="#S14.4"> Clinical Studies (14.4)</a></span>].</p>
</div>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="S12.3"></a><a name="section-11.3"></a><p></p>
<h2>12.3	Pharmacokinetics</h2>
<p class="First">In animal studies, following intravitreal injection, ranibizumab was cleared from the vitreous with a half-life of approximately 3 days. After reaching a maximum at approximately 1 day, the serum concentration of ranibizumab declined in parallel with the vitreous concentration. In these animal studies, systemic exposure of ranibizumab was more than 2000-fold lower than in the vitreous.</p>
<p>In patients with neovascular AMD, following monthly intravitreal administration of 0.5 mg LUCENTIS, mean (±SD)maximum ranibizumab serum concentrations were 1.7 (± 1.1) ng/mL These concentrations were below the concentration range of ranibizumab (11 ng/mL to 27 ng/mL) that was necessary to inhibit the biological activity of VEGF-A by 50%, as measured in an in vitro cellular proliferation assay (based on human umbilical vein endothelial cells (HUVEC)). No significant change from baseline was observed in the mean plasma VEGF concentrations following three monthly 0.5 mg intravitreal injections. The maximum observed serum concentration was dose proportional over the dose range of 0.05 to 2 mg/eye.  Serum ranibizumab concentrations in RVO and DME and DR patients were similar to those observed in neovascular AMD patients.</p>
<p>Based on a population pharmacokinetic analysis of patients with neovascular AMD, maximum serum concentrations are predicted to be reached at approximately 1 day after monthly intravitreal administration of LUCENTIS 0.5 mg/eye. Based on the disappearance of ranibizumab from serum, the estimated average vitreous elimination half-life was approximately 9 days. Steady-state minimum concentration is predicted to be 0.22 ng/mL with a monthly dosing regimen. In humans, serum ranibizumab concentrations are predicted to be approximately 90,000-fold lower than vitreal concentrations.</p>
<p>In pharmacokinetic covariate analyses, 48% (520/1091) of patients had <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (35% mild, 11% moderate, and 2% severe). Because the increases in plasma ranibizumab exposures in these patients are not considered clinically significant, no dosage adjustment is needed based on <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> status.</p>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="S13"></a><a name="section-12"></a><p></p>
<h1>13	NONCLINICAL TOXICOLOGY</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="S13.1"></a><a name="section-12.1"></a><p></p>
<h2>13.1	Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">No carcinogenicity or mutagenicity data are available for ranibizumab injection in animals or humans.</p>
<p>No studies on the effects of ranibizumab on fertility have been conducted. Although systemic exposure following ocular administration is expected to be low, effects on female fertility are possible due to the anti-VEGF mechanism of action for ranibizumab [<span class="Italics">see<a href="#S12.1"> Clinical Pharmacology (12.1)</a></span>].</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="S14"></a><a name="section-13"></a><p></p>
<h1>14	CLINICAL STUDIES</h1>
<p class="First">Unless otherwise noted, visual acuity was measured at a distance of 4 meters.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="S14.1"></a><a name="section-13.1"></a><p></p>
<h2>14.1	Neovascular (Wet) Age-Related <span class="product-label-link" type="condition" conceptid="4083487" conceptname="Macular drusen">Macular Degeneration</span> (AMD)</h2>
<p class="First">The safety and efficacy of LUCENTIS were assessed in three randomized, double-masked, sham- or active-controlled studies in patients with neovascular AMD. A total of 1323 patients (LUCENTIS 879, control 444) were enrolled in the three studies.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-13.1.1"></a><p></p>
<p class="First"><span class="Italics">Studies AMD-1 and AMD-2</span></p>
<p>In Study AMD-1<span class="Italics">,</span> patients with minimally classic or occult (without classic) CNV lesions received monthly LUCENTIS 0.3 mg or 0.5 mg intravitreal injections or monthly sham injections. Data are available through Month 24. Patients treated with LUCENTIS in Study AMD-1 received a mean of 22 total treatments out of a possible 24 from Day 0 to Month 24.</p>
<p>In Study AMD-2, patients with predominantly classic CNV lesions received one of the following:  1) monthly LUCENTIS 0.3 mg intravitreal injections and sham PDT; 2) monthly LUCENTIS 0.5 mg intravitreal injections and sham PDT; or 3) sham intravitreal injections and active verteporfin PDT. Sham PDT (or active verteporfin PDT) was given with the initial LUCENTIS (or sham) intravitreal injection and every 3 months thereafter if fluorescein angiography showed persistence or recurrence of leakage. Data are available through Month 24. Patients treated with LUCENTIS in Study AMD-2 received a mean of 21 total treatments out of a possible 24 from Day 0 through Month 24.</p>
<p>In both studies, the primary efficacy endpoint was the proportion of patients who maintained vision, defined as losing fewer than 15 letters of visual acuity at 12 months compared with baseline. Almost all LUCENTIS-treated patients (approximately 95%) maintained their visual acuity. Among LUCENTIS-treated patients, 31% to 37% experienced a clinically significant improvement in vision, defined as gaining 15 or more letters at 12 months. The size of the lesion did not significantly affect the results. Detailed results are shown in<a href="#table3"> Table 3</a>,<a href="#table4"> Table 4</a>, and<a href="#fig1"> Figure 1 </a>below.</p>
<a name="table3"></a><table width="75%">
<caption><span>Table 3 Visual Acuity Outcomes at Month 12 and Month 24 in Study AMD-1</span></caption>
<col align="left" valign="top" width="27%">
<col align="center" valign="top" width="15%">
<col align="center" valign="top" width="18%">
<col align="center" valign="top" width="20%">
<col align="center" valign="top" width="20%">
<thead><tr class="Botrule First Last">
<th class="Lrule" align="center" valign="bottom">Outcome Measure</th>
<th align="center" valign="bottom">Month</th>
<th align="center" valign="bottom">Sham<br>n=229</th>
<th align="center" valign="bottom">LUCENTIS<br>0.5 mg<br>n=230</th>
<th class="Rrule" align="center" valign="bottom">Estimated<br>Difference<br>(95% CI)<a name="footnote-reference-1" href="#footnote-1" class="Sup">*</a>
</th>
</tr></thead>
<tfoot><tr><td colspan="5" align="left"><dl class="Footnote">
<dt><a name="footnote-1" href="#footnote-reference-1">*</a></dt>
<dd>Adjusted estimate based on the stratified model;  p &lt; 0.01</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="First">
<td class="Botrule Lrule" align="left" rowspan="2">Loss of &lt;15 letters in visual acuity (%)</td>
<td align="center">12</td>
<td align="center">60%</td>
<td align="center">91%</td>
<td class="Rrule" align="center">30%<br>(23%, 37%)</td>
</tr>
<tr class="Botrule">
<td align="center">24</td>
<td align="center">56%</td>
<td align="center">89%</td>
<td class="Rrule" align="center">33%<br>(26%, 41%)</td>
</tr>
<tr>
<td class="Botrule Lrule" align="left" rowspan="2">Gain of ≥15 letters in visual acuity (%)</td>
<td align="center">12</td>
<td align="center">6%</td>
<td align="center">31%</td>
<td class="Rrule" align="center">25%<br>(18%, 31%)</td>
</tr>
<tr class="Botrule">
<td align="center">24</td>
<td align="center">4%</td>
<td align="center">30%</td>
<td class="Rrule" align="center">25%<br>(18%, 31%)</td>
</tr>
<tr>
<td class="Botrule Lrule" align="left" rowspan="2">Mean change in visual acuity (letters) (SD)</td>
<td align="center">12</td>
<td align="center">−11.0 (17.9)</td>
<td align="center">+6.3 ( 14.1)</td>
<td class="Rrule" align="center">17.1<br>(14.2, 20.0)</td>
</tr>
<tr class="Botrule Last">
<td align="center">24</td>
<td align="center">−15.0 (19.7)</td>
<td align="center">+5.5 ( 15.9)</td>
<td class="Rrule" align="center">20.1<br>(16.9, 23.4)</td>
</tr>
</tbody>
</table>
<a name="table4"></a><table width="75%">
<caption><span>Table 4 Visual Acuity Outcomes at Month 12 and Month 24 in Study AMD-2</span></caption>
<col align="left" valign="top" width="27%">
<col align="center" valign="top" width="15%">
<col align="center" valign="top" width="18%">
<col align="center" valign="top" width="20%">
<col align="center" valign="top" width="20%">
<thead><tr class="Botrule First Last">
<th class="Lrule" align="center" valign="bottom">Outcome Measure</th>
<th align="center" valign="bottom">Month</th>
<th align="center" valign="bottom">Verteporfin PDT<br>n=141</th>
<th align="center" valign="bottom">LUCENTIS<br>0.5 mg<br>n=139</th>
<th class="Rrule" align="center" valign="bottom">Estimated<br>Difference<br>(95% CI)<a name="footnote-reference-2" href="#footnote-2" class="Sup">*</a>
</th>
</tr></thead>
<tfoot><tr><td colspan="5" align="left"><dl class="Footnote">
<dt><a name="footnote-2" href="#footnote-reference-2">*</a></dt>
<dd>Adjusted estimate based on the stratified model;  p &lt; 0.01</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="First">
<td class="Botrule Lrule" align="left" rowspan="2">Loss of &lt;15 letters in visual acuity (%)</td>
<td align="center">12</td>
<td align="center">66%</td>
<td align="center">98%</td>
<td class="Rrule" align="center">32%<br>(24%, 40%)</td>
</tr>
<tr class="Botrule">
<td align="center">24</td>
<td align="center">65%</td>
<td align="center">93%</td>
<td class="Rrule" align="center">28%<br>(19%, 37%)</td>
</tr>
<tr>
<td class="Botrule Lrule" align="left" rowspan="2">Gain of ≥15 letters in visual acuity (%)</td>
<td align="center">12</td>
<td align="center">11%</td>
<td align="center">37%</td>
<td class="Rrule" align="center">26%<br>(17%, 36%)</td>
</tr>
<tr class="Botrule">
<td align="center">24</td>
<td align="center">9%</td>
<td align="center">37%</td>
<td class="Rrule" align="center">29%<br>(20%, 39%)</td>
</tr>
<tr>
<td class="Botrule Lrule" align="left" rowspan="2">Mean change in visual acuity (letters) (SD)</td>
<td align="center">12</td>
<td align="center">−8.5 (17.8)</td>
<td align="center">+11.0 (15.8)</td>
<td class="Rrule" align="center">19.8<br>(15.9, 23.7)</td>
</tr>
<tr class="Botrule Last">
<td align="center">24</td>
<td align="center">−9.1 (18.7)</td>
<td align="center">+10.9 (17.3)</td>
<td class="Rrule" align="center">20<br>(16.0, 24.4)</td>
</tr>
</tbody>
</table>
<a name="fig1"></a><table class="Noautorules" width="100%">
<col align="center" valign="top" width="100%">
<tbody class="Headless">
<tr><td align="center">
<span class="Bold">Figure 1</span><br>Mean Change in Visual Acuity from Baseline<br>to Month 24 in Study AMD-1 and Study AMD-2</td></tr>
<tr><td align="center"><img alt="Figure 1" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=de4e66cc-ca05-4dc9-8262-e00e9b41c36d&amp;name=lucentis-01.jpg"></td></tr>
</tbody>
</table>
<p>                 Visual acuity was measured at a distance of 2 meters</p>
<p>Patients in the group treated with LUCENTIS had minimal observable CNV lesion growth, on average. At Month 12, the mean change in the total area of the CNV lesion was 0.1-0.3 disc areas (DA) for LUCENTIS versus 2.3-2.6 DA for the control arms. At Month 24, the mean change in the total area of the CNV lesion was 0.3-0.4 DA for LUCENTIS versus 2.9-3.1 DA for the control arms.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-13.1.2"></a><p></p>
<p class="First"><span class="Italics">Study AMD-3</span></p>
<p>Study AMD-3 was a randomized, double-masked, sham-controlled, two-year study designed to assess the safety and efficacy of LUCENTIS in patients with neovascular AMD (with or without a classic CNV component). Data are available through Month 12. Patients received LUCENTIS 0.3 mg or 0.5 mg intravitreal injections or sham injections once a month for 3 consecutive doses, followed by a dose administered once every 3 months for 9 months. A total of 184 patients were enrolled in this study (LUCENTIS 0.3 mg, 60; LUCENTIS 0.5 mg, 61; sham, 63); 171 (93%) completed 12 months of this study. Patients treated with LUCENTIS in Study AMD-3 received a mean of 6 total treatments out of a possible 6 from Day 0 through Month 12.</p>
<p>In Study AMD-3, the primary efficacy endpoint was mean change in visual acuity at 12 months compared with baseline (see<a href="#fig2"> Figure 2</a>). After an initial increase in visual acuity (following monthly dosing), on average, patients dosed once every 3 months with LUCENTIS lost visual acuity, returning to baseline at Month 12. In Study AMD-3, almost all LUCENTIS-treated patients (90%) lost fewer than 15 letters of visual acuity at Month 12.</p>
<a name="fig2"></a><table class="Noautorules" width="100%">
<col align="center" valign="top" width="100%">
<tbody class="Headless">
<tr><td align="center">
<span class="Bold">Figure 2</span><br>Mean Change in Visual Acuity from Baseline to Month 12 in Study AMD-3</td></tr>
<tr><td align="center"><img alt="Figure 2" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=de4e66cc-ca05-4dc9-8262-e00e9b41c36d&amp;name=lucentis-02.jpg"></td></tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-13.1.3"></a><p></p>
<p class="First"><span class="Italics">Study AMD-4</span></p>
<p>Study AMD-4 was a randomized, double-masked, active treatment-controlled, two-year study designed to assess the safety and efficacy of LUCENTIS 0.5 mg administered monthly or less frequently than monthly in patients with neovascular AMD.  Patients randomized to the LUCENTIS 0.5 mg less frequent dosing arm received 3 monthly doses followed by monthly assessments where patients were eligible to receive LUCENTIS injections guided by pre-specified re-treatment criteria.  A total of 550 patients were enrolled in the two 0.5 mg treatment groups with 467 (85%) completing through Month 24. Data are available through Month 24. Clinical results at Month 24 remain similar to that observed at Month 12.</p>
<p>From Month 3 through Month 24, <span class="product-label-link" type="condition" conceptid="376402" conceptname="Low vision, one eye">visual acuity decreased</span> by 0.3 letters in the 0.5 mg less frequent dosing arm and increased by 0.7 letters in the 0.5 mg monthly arm (see <a href="#fig3">Figure 3</a>).  Over this 21 month period, patients in the 0.5 mg less frequent dosing and the 0.5 mg monthly arms averaged 10.3 and 18.5 injections, respectively.  The distribution of injections received in the less frequent dosing arm is shown in Figure 4.</p>
<a name="fig3"></a><table class="Noautorules" width="100%">
<col align="center" valign="top" width="100%">
<tbody class="Headless">
<tr><td align="center">
<span class="Bold">Figure 3</span><br>Mean Change in Visual Acuity from Baseline to Month 24 in Study AMD-4</td></tr>
<tr><td align="center"><img alt="Figure 3" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=de4e66cc-ca05-4dc9-8262-e00e9b41c36d&amp;name=lucentis-03.jpg"></td></tr>
</tbody>
</table>
<a name="fig4"></a><table class="Noautorules" width="100%">
<col align="center" valign="top" width="100%">
<tbody class="Headless">
<tr><td align="center">
<span class="Bold">Figure 4</span><br>Distribution of Injections from Month 3 to Month 24 in the Less Frequent Dosing Arm in Study AMD-4</td></tr>
<tr><td align="center"><img alt="Figure 4" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=de4e66cc-ca05-4dc9-8262-e00e9b41c36d&amp;name=lucentis-04.jpg"></td></tr>
</tbody>
</table>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S14.2"></a><a name="section-13.2"></a><p></p>
<h2>14.2	<span class="product-label-link" type="condition" conceptid="4290333" conceptname="Macular retinal edema">Macular Edema</span> Following <span class="product-label-link" type="condition" conceptid="313761" conceptname="Central retinal vein occlusion">Retinal Vein Occlusion</span> (RVO)</h2>
<p class="First">The safety and efficacy of LUCENTIS were assessed in two randomized, double-masked, 1-year studies in patients with <span class="product-label-link" type="condition" conceptid="4290333" conceptname="Macular retinal edema">macular edema</span> following RVO. Sham controlled data are available through Month 6. Patient age ranged from 20 to 91 years, with a mean age of 67 years. A total of 789 patients (LUCENTIS 0.3 mg, 266 patients; LUCENTIS 0.5 mg, 261 patients; sham, 262 patients) were enrolled, with 739 (94%) patients completing through Month 6. All patients completing Month 6 were eligible to receive LUCENTIS injections guided by pre-specified re-treatment criteria until the end of the studies at Month 12.</p>
<p>In Study RVO-1, patients with <span class="product-label-link" type="condition" conceptid="4290333" conceptname="Macular retinal edema">macular edema</span> following branch or hemi-RVO, received monthly LUCENTIS 0.3 mg or 0.5 mg intravitreal injections or monthly sham injections for 6 months. All patients were eligible for macular focal/grid laser treatment beginning at Month 3 of the 6-month treatment period. Macular focal/grid laser treatment was given to 26 of 131 (20%) patients treated with 0.5 mg LUCENTIS and 71 of 132 (54%) patients treated with sham.</p>
<p>In Study RVO-2, patients with <span class="product-label-link" type="condition" conceptid="4290333" conceptname="Macular retinal edema">macular edema</span> following central RVO received monthly LUCENTIS 0.3 mg or 0.5 mg intravitreal injections or monthly sham injections for 6 months.</p>
<p>At Month 6, after monthly treatment with 0.5 mg LUCENTIS, the following clinical results were observed: </p>
<a name="table5"></a><table width="75%">
<caption><span>Table 5 Visual Acuity Outcomes at Month 6 in Study RVO-1 and Study RVO-2</span></caption>
<col align="left" valign="middle" width="25%">
<col align="center" valign="middle" width="15%">
<col align="center" valign="middle" width="20%">
<col align="center" valign="middle" width="20%">
<col align="center" valign="middle" width="20%">
<thead><tr class="First Last">
<th class="Lrule" align="center" valign="bottom">Outcome Measure</th>
<th align="center" valign="bottom">Study <a name="footnote-reference-3" href="#footnote-3" class="Sup">*</a>
</th>
<th align="center" valign="bottom">Sham</th>
<th align="center" valign="bottom">LUCENTIS<br>0.5 mg</th>
<th class="Rrule" align="center" valign="bottom">Estimated Difference<br>(95% CI) <a name="footnote-reference-4" href="#footnote-4" class="Sup">†</a>
</th>
</tr></thead>
<tfoot><tr><td colspan="5" align="left"><dl class="Footnote">
<dt><a name="footnote-3" href="#footnote-reference-3">*</a></dt>
<dd>RVO-1: Sham, n=131; LUCENTIS 0.5 mg, n=132<br>RVO-2: Sham, n=130; LUCENTIS 0.5 mg, n=130</dd>
<dt><a name="footnote-4" href="#footnote-reference-4">†</a></dt>
<dd>Adjusted estimate based on stratified model;  p &lt; 0.01</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="Botrule First">
<td class="Lrule" align="left">Gain of ≥15 letters in visual acuity (%)</td>
<td align="center">RVO-1</td>
<td align="center">29%</td>
<td align="center">61%</td>
<td class="Rrule" align="center">31%<br>(20%, 43%)</td>
</tr>
<tr class="Botrule Last">
<td class="Lrule" align="left">Gain of ≥15 letters in visual acuity (%)</td>
<td align="center">RVO-2</td>
<td align="center">17%</td>
<td align="center">48%</td>
<td class="Rrule" align="center">30%<br>(20%, 41%)</td>
</tr>
</tbody>
</table>
<a name="fig5"></a><table class="Noautorules" width="100%">
<col align="center" valign="top" width="100%">
<tbody class="Headless">
<tr><td align="center">
<span class="Bold">Figure 5</span><br>Mean Change in Visual Acuity from Baseline to Month 6 in Study RVO-1 and Study RVO-2</td></tr>
<tr><td align="center"><img alt="Figure 5" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=de4e66cc-ca05-4dc9-8262-e00e9b41c36d&amp;name=lucentis-05.jpg"></td></tr>
</tbody>
</table>
<p>          p &lt; 0.01 for all time points</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S14.3"></a><a name="section-13.3"></a><p></p>
<h2>14.3	<span class="product-label-link" type="condition" conceptid="380097" conceptname="Diabetic macular edema">Diabetic Macular Edema</span> (DME)</h2>
<p class="First">Efficacy and safety data of LUCENTIS are derived from studies D-1 and D-2 (See <a href="#S14.4">Section 14.4 <span class="product-label-link" type="condition" conceptid="4174977" conceptname="Diabetic retinopathy">Diabetic Retinopathy</span></a> below). All enrolled patients had DR and DME at baseline.</p>
<p>The safety and efficacy of LUCENTIS were assessed in two randomized, double-masked, 3-year studies in patients with DME. The studies were sham-controlled through Month 24. Patient age ranged from 21 to 91 years, with a mean age of 62 years. A total of 759 patients (LUCENTIS 0.3 mg, 250 patients; LUCENTIS 0.5 mg, 252 patients; sham, 257 patients) were enrolled, with 582 (77%) completing through Month 36.</p>
<p>In Studies D-1 and D-2, patients received monthly LUCENTIS 0.3 mg or 0.5 mg intravitreal injections or monthly sham injections during the 24-month controlled treatment period. From Months 25 through 36, patients who previously received sham were eligible to receive monthly LUCENTIS 0.5 mg and patients originally randomized to monthly LUCENTIS 0.3 mg or 0.5 mg continued to receive their assigned dose. All patients were eligible for macular focal/grid laser treatment beginning at Month 3 of the 24-month treatment period or panretinal photocoagulation (PRP) as needed. Through Month 24, macular focal/grid laser treatment was administered in 94 of 250 (38%) patients treated with LUCENTIS 0.3 mg and 185 of 257 (72%) patients treated with sham; PRP was administered in 2 of 250 (1%) patients treated with LUCENTIS 0.3 mg and 30 of 257 (12%) patients treated with sham.</p>
<p>Compared to monthly LUCENTIS 0.3 mg, no additional benefit was observed with monthly treatment with LUCENTIS 0.5 mg. At Month 24, after monthly treatment with LUCENTIS 0.3 mg, the following clinical results were observed:</p>
<table width="75%">
<caption><span>Table 6 Visual Acuity Outcomes at Month 24 in Study D-1 and Study D-2</span></caption>
<col align="left" valign="middle" width="25%">
<col align="center" valign="middle" width="15%">
<col align="center" valign="middle" width="20%">
<col align="center" valign="middle" width="20%">
<col align="center" valign="middle" width="20%">
<thead><tr class="Botrule First Last">
<th class="Lrule" align="center" valign="bottom">Outcome Measure</th>
<th align="center" valign="bottom">Study<a name="footnote-reference-5" href="#footnote-5" class="Sup">*</a>
</th>
<th align="center" valign="bottom">Sham</th>
<th align="center" valign="bottom">LUCENTIS<br>0.3 mg</th>
<th class="Rrule" align="center" valign="bottom">Estimated<br>Difference<br>(95% CI)<a name="footnote-reference-6" href="#footnote-6" class="Sup">†</a>
</th>
</tr></thead>
<tfoot><tr><td colspan="5" align="left"><dl class="Footnote">
<dt><a name="footnote-5" href="#footnote-reference-5">*</a></dt>
<dd>D-1: Sham, n=130; LUCENTIS 0.3 mg, n=125<br>D-2: Sham, n=127; LUCENTIS 0.3 mg, n=125</dd>
<dt><a name="footnote-6" href="#footnote-reference-6">†</a></dt>
<dd>Adjusted estimate based on stratified model;  p ≤ 0.01</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="First">
<td class="Botrule Lrule" align="left" rowspan="2">Gain of ≥15 letters in visual acuity (%)</td>
<td align="center">D-1</td>
<td align="center">12%</td>
<td align="center">34%</td>
<td class="Rrule" align="center">21%<br>(11%, 30%)</td>
</tr>
<tr class="Botrule">
<td align="center">D-2</td>
<td align="center">18%</td>
<td align="center">45%</td>
<td class="Rrule" align="center">24%<br>(14%, 35%)</td>
</tr>
<tr>
<td class="Botrule Lrule" align="left" rowspan="2">Loss of &lt;15 letters in visual acuity (%)</td>
<td align="center">D-1</td>
<td align="center">92%</td>
<td align="center">98%</td>
<td class="Rrule" align="center">7%<br>(2%, 13%)</td>
</tr>
<tr class="Botrule">
<td align="center">D-2</td>
<td align="center">90%</td>
<td align="center">98%</td>
<td class="Rrule" align="center">8%<br>(2%, 14%)</td>
</tr>
<tr>
<td class="Botrule Lrule" align="left" rowspan="2">Mean change in visual acuity (letters)</td>
<td align="center">D-1</td>
<td align="center">2.3</td>
<td align="center">10.9</td>
<td class="Rrule" align="center">8.5<br>(5.4, 11.5)</td>
</tr>
<tr class="Botrule Last">
<td align="center">D-2</td>
<td align="center">2.6</td>
<td align="center">12.5</td>
<td class="Rrule" align="center">9.6<br>(6.1, 13.0)</td>
</tr>
</tbody>
</table>
<a name="fig6"></a><table class="Noautorules" width="100%">
<col align="center" valign="top" width="100%">
<tbody class="Headless">
<tr><td align="center">
<span class="Bold">Figure 6</span><br>Mean Change in Visual Acuity from Baseline to Month 36 in Study D-1 and Study D-2</td></tr>
<tr><td align="center"><img alt="Figure 6" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=de4e66cc-ca05-4dc9-8262-e00e9b41c36d&amp;name=lucentis-06.jpg"></td></tr>
</tbody>
</table>
<p>p &lt; 0.01 for all time points comparing LUCENTIS 0.3 mg to sham through Month 24</p>
<p>VA outcomes observed at Month 24 in patients treated with LUCENTIS 0.3 mg were maintained with continued treatment through Month 36 in both DME studies. Patients in the sham arms who received LUCENTIS 0.5 mg beginning at Month 25 achieved lesser VA gains compared to patients who began treatment with LUCENTIS at the beginning of the studies.</p>
<p>In Studies D-1 and D-2, patients received monthly injections of LUCENTIS for 12 or 36 months, after which 500 patients opted to continue in the long-term follow-up study.  Of 298 patients who had at least 12 months of follow-up from Month 36, 58 (19.5%) patients maintained vision with no further therapy.  The remaining 202 patients were followed for less than 12 months.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S14.4"></a><a name="section-13.4"></a><p></p>
<h2>14.4	<span class="product-label-link" type="condition" conceptid="4174977" conceptname="Diabetic retinopathy">Diabetic Retinopathy</span> in patients with <span class="product-label-link" type="condition" conceptid="380097" conceptname="Diabetic macular edema">Diabetic Macular Edema</span> (DME)</h2>
<p class="First">Efficacy and safety data of LUCENTIS are derived from studies D-1 and D-2 (See <a href="#S14.3">Section 14.3 <span class="product-label-link" type="condition" conceptid="380097" conceptname="Diabetic macular edema">Diabetic Macular Edema</span></a> above). All enrolled patients had DR and DME at baseline.</p>
<p>Of the 759 patients enrolled, 746 patients had a baseline assessment of fundus photography. Patients had baseline Early Treatment <span class="product-label-link" type="condition" conceptid="4174977" conceptname="Diabetic retinopathy">Diabetic Retinopathy</span> Study (ETDRS) <span class="product-label-link" type="condition" conceptid="376103" conceptname="Retinopathy">Retinopathy</span> Severity Scores (ETDRS-RSS) ranging from 10 to 75. At baseline, 62% of patients had NPDR (ETDRS-RSS less than 60) and 31% had PDR (ETDRS-RSS greater than or equal to 60). </p>
<p>The ETDRS-RSS could not be graded in 5% of patients at baseline, and 2% of patients had absent or questionable DR at baseline.  Approximately 20% of the overall population had prior PRP. </p>
<p>After monthly treatment with LUCENTIS 0.3 mg, the following clinical results were observed (<a href="#table7">Table 7</a>; <a href="#fig7">Figure 7</a>):</p>
<a name="table7"></a><table width="75%">
<caption><span>Table 7 ≥3-step and ≥2-step improvement at Month 24 in Study D-1 and Study D-2</span></caption>
<col align="left" valign="middle" width="25%">
<col align="left" valign="middle" width="15%">
<col align="left" valign="middle" width="20%">
<col align="left" valign="middle" width="20%">
<col align="left" valign="middle" width="20%">
<thead><tr class="Botrule First Last">
<th class="Lrule" align="left" valign="bottom">Outcome Measure</th>
<th align="left" valign="bottom">Study<a name="footnote-reference-7" href="#footnote-7" class="Sup">*</a>
</th>
<th align="left" valign="bottom">Sham</th>
<th align="left" valign="bottom">LUCENTIS<br>0.3 mg</th>
<th class="Rrule" align="left" valign="bottom">Estimated<br>Difference<br>(95% CI)<a name="footnote-reference-8" href="#footnote-8" class="Sup">†</a>
</th>
</tr></thead>
<tfoot><tr><td colspan="5" align="left"><dl class="Footnote">
<dt><a name="footnote-7" href="#footnote-reference-7">*</a></dt>
<dd>D-1: Sham, n=124; LUCENTIS 0.3 mg, n=117<br>D-2: Sham, n=115; LUCENTIS 0.3 mg, n=117</dd>
<dt><a name="footnote-8" href="#footnote-reference-8">†</a></dt>
<dd>Adjusted estimate based on stratified model</dd>
<dt><a name="footnote-9" href="#footnote-reference-9">‡</a></dt>
<dd>p &lt; 0.05 for all time points comparing LUCENTIS 0.3 mg to sham from Month 12 through Month 24</dd>
<dt><a name="footnote-10" href="#footnote-reference-10">§</a></dt>
<dd>p &lt; 0.05 for all time points comparing LUCENTIS 0.3 mg to sham from Month 3 through Month 24</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="First">
<td class="Botrule Lrule" align="left" rowspan="2">≥3-step improvement from baseline in ETDRS-DRSS <a name="footnote-reference-9" href="#footnote-9" class="Sup">‡</a>
</td>
<td align="left">D-1</td>
<td align="left">2%</td>
<td align="left">17%</td>
<td class="Rrule" align="left">15%<br>(7%, 22%)</td>
</tr>
<tr class="Botrule">
<td align="left">D-2</td>
<td align="left">0%</td>
<td align="left">9%</td>
<td class="Rrule" align="left">9%<br>(4%, 14%)</td>
</tr>
<tr>
<td class="Botrule Lrule" align="left" rowspan="2">≥2-step improvement from baseline in ETDRS-DRSS <a name="footnote-reference-10" href="#footnote-10" class="Sup">§</a>
</td>
<td align="left">D-1</td>
<td align="left">4%</td>
<td align="left">39%</td>
<td class="Rrule" align="left">35%<br>(26%, 44%)</td>
</tr>
<tr class="Last">
<td align="left">D-2</td>
<td align="left">7%</td>
<td align="left">37%</td>
<td class="Rrule" align="left">31%<br>(21%, 40%)</td>
</tr>
</tbody>
</table>
<p>At Month 24, DR improvement by ≥3-steps in ETDRS-RSS from baseline in subgroups examined (e.g., age, gender, race, baseline visual acuity, baseline HbA1c, prior DME therapy at baseline, baseline DR severity (NPDR, PDR)) were generally consistent with the results in the overall population. </p>
<p>The difference in the proportion of patients treated with LUCENTIS 0.3 mg compared to sham who achieved DR improvement based on the ETDRS-RSS was observed as early as Month 3 for ≥2-step improvement or at Month 12 for ≥3-step improvement.</p>
<a name="fig7"></a><table class="Noautorules" width="100%">
<col align="center" valign="top" width="100%">
<tbody class="Headless">
<tr><td align="center">
<span class="Bold">Figure 7</span><br>Proportion of Patients with ≥3-Step and ≥2-Step Improvement from Baseline in ETDRS <span class="product-label-link" type="condition" conceptid="4174977" conceptname="Diabetic retinopathy">Diabetic Retinopathy</span> Severity Level over Time in Study D-1 and Study D-2</td></tr>
<tr><td align="center"><img alt="Figure 7" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=de4e66cc-ca05-4dc9-8262-e00e9b41c36d&amp;name=lucentis-07.jpg"></td></tr>
</tbody>
</table>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="S16"></a><a name="section-14"></a><p></p>
<h1>16	HOW SUPPLIED/STORAGE AND HANDLING</h1>
<ul>
<li> Each LUCENTIS 0.5 mg carton (NDC 50242-080-01) contains a single-use, 2-cc glass vial with a BLUE CAP designed to deliver 0.05 mL of 10 mg/mL ranibizumab.</li>
<li> Each LUCENTIS 0.3 mg carton (NDC 50242-082-01) contains a single-use, 2-cc glass vial with a WHITE CAP designed to deliver 0.05 mL of 6 mg/mL ranibizumab.</li>
</ul>
<p class="First">In addition, each carton contains one 5-micron, 19-gauge × 1-1/2-inch filter needle for withdrawal of the vial contents; one 30-gauge × 1/2-inch injection needle for the intravitreal injection; and one package insert [<span class="Italics">see<a href="#S2.6"> Dosage and Administration (2.6)</a></span>]. VIALS ARE FOR SINGLE-EYE USE ONLY.</p>
<div class="Section" data-sectionCode="44425-7">
<a name="section-14.1"></a><p></p>
<p class="First">LUCENTIS should be refrigerated at 2°-8°C (36°-46°F). DO NOT FREEZE. Do not use beyond the date stamped on the label. LUCENTIS vials should be protected from light. Store in the original carton until time of use.</p>
</div>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="S17"></a><a name="section-15"></a><p></p>
<h1>17	PATIENT COUNSELING INFORMATION</h1>
<p class="First">Advise patients that in the days following LUCENTIS administration, patients are at risk of developing <span class="product-label-link" type="condition" conceptid="438411" conceptname="Endophthalmitis">endophthalmitis</span>. If the eye becomes red, sensitive to light, painful, or develops a change in vision, the patient should seek immediate care from an ophthalmologist [<span class="Italics">see<a href="#S5.1"> Warnings and Precautions (5.1)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-16"></a><p></p>
<p class="First"><span class="Bold">LUCENTIS<span class="Sup">®</span> [ranibizumab injection]</span></p>
<p>Manufactured by:<br><span class="Bold">Genentech, Inc.</span><br>A Member of the Roche Group<br>1 DNA Way<br>South San Francisco, CA 94080-4990</p>
<p>LUCENTIS<span class="Sup">®</span> is a registered<br>trademark of Genentech, Inc.<br><span class="Sup">©</span>2015 Genentech, Inc.</p>
<p>Representative sample of labeling (see the<a href="#S16"> HOW SUPPLIED </a>section for complete listing):</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-17"></a><p></p>
<p class="First"><span class="Bold">PRINCIPAL DISPLAY PANEL - 0.5 mg Vial Carton</span></p>
<p>NDC 50242-080-01</p>
<p><span class="Bold">LUCENTIS</span><span class="Sup">®</span><br>RANIBIZUMAB INJECTION</p>
<p><span class="Bold">0.5 mg DOSE SINGLE-USE VIAL</span></p>
<p><span class="Bold">INDICATED FOR<br>Neovascular (wet) age-related <span class="product-label-link" type="condition" conceptid="4083487" conceptname="Macular drusen">macular degeneration</span> (wAMD)<br><span class="product-label-link" type="condition" conceptid="4290333" conceptname="Macular retinal edema">Macular edema</span> following <span class="product-label-link" type="condition" conceptid="313761" conceptname="Central retinal vein occlusion">retinal vein occlusion</span> (RVO)</span></p>
<p><span class="Bold">0.5 mg     wAMD | RVO</span></p>
<p><span class="Bold">For intravitreal injection only.</span></p>
<p><span class="Bold">KEEP REFRIGERATED. DO NOT FREEZE.<br>PROTECT VIAL FROM DIRECT SUNLIGHT.</span></p>
<p><span class="Bold">Rx only</span></p>
<p><span class="Bold">Genentech</span></p>
<p>10149810</p>
<div class="Figure"><img alt="PRINCIPAL DISPLAY PANEL - 0.5 mg Vial Carton" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=de4e66cc-ca05-4dc9-8262-e00e9b41c36d&amp;name=lucentis-08.jpg"></div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-18"></a><p></p>
<p class="First"><span class="Bold">PRINCIPAL DISPLAY PANEL - 0.3 mg Vial Carton</span></p>
<p>NDC 50242-082-01</p>
<p><span class="Bold">LUCENTIS</span><span class="Sup">®</span><br>RANIBIZUMAB INJECTION</p>
<p><span class="Bold">0.3 mg DOSE SINGLE-USE VIAL</span></p>
<p><span class="Bold">INDICATED FOR<br><span class="product-label-link" type="condition" conceptid="380097" conceptname="Diabetic macular edema">Diabetic macular edema</span> (DME)<br><span class="product-label-link" type="condition" conceptid="4174977" conceptname="Diabetic retinopathy">Diabetic retinopathy</span> (DR) with DME</span></p>
<p><span class="Bold">0.3 mg     DME | DR with DME</span></p>
<p><span class="Bold">For intravitreal injection only.</span></p>
<p><span class="Bold">KEEP REFRIGERATED. DO NOT FREEZE.<br>PROTECT VIAL FROM DIRECT SUNLIGHT.</span></p>
<p><span class="Bold">Rx only</span></p>
<p><span class="Bold">Genentech</span></p>
<p>10149808</p>
<div class="Figure"><img alt="PRINCIPAL DISPLAY PANEL - 0.3 mg Vial Carton" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=de4e66cc-ca05-4dc9-8262-e00e9b41c36d&amp;name=lucentis-09.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>LUCENTIS 		
					</strong><br><span class="contentTableReg">ranibizumab injection, solution</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:50242-080</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAVITREAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>RANIBIZUMAB</strong> (RANIBIZUMAB) </td>
<td class="formItem">RANIBIZUMAB</td>
<td class="formItem">10 mg  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>HISTIDINE MONOHYDROCHLORIDE</strong></td>
<td class="formItem">1.66 mg  in 1 mL</td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>HISTIDINE</strong></td>
<td class="formItem">0.32 mg  in 1 mL</td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TREHALOSE DIHYDRATE</strong></td>
<td class="formItem">100 mg  in 1 mL</td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POLYSORBATE 20</strong></td>
<td class="formItem">0.1 mg  in 1 mL</td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>WATER</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:50242-080-01</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">0.05 mL in 1 VIAL, SINGLE-USE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">BLA</td>
<td class="formItem">BLA125156</td>
<td class="formItem">06/30/2006</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>LUCENTIS 		
					</strong><br><span class="contentTableReg">ranibizumab injection, solution</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:50242-082</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAVITREAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>RANIBIZUMAB</strong> (RANIBIZUMAB) </td>
<td class="formItem">RANIBIZUMAB</td>
<td class="formItem">6 mg  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>HISTIDINE MONOHYDROCHLORIDE</strong></td>
<td class="formItem">1.66 mg  in 1 mL</td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>HISTIDINE</strong></td>
<td class="formItem">0.32 mg  in 1 mL</td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TREHALOSE DIHYDRATE</strong></td>
<td class="formItem">100 mg  in 1 mL</td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POLYSORBATE 20</strong></td>
<td class="formItem">0.1 mg  in 1 mL</td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>WATER</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:50242-082-01</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">0.05 mL in 1 VIAL, SINGLE-USE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">BLA</td>
<td class="formItem">BLA125156</td>
<td class="formItem">08/10/2012</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Genentech, Inc.
							(080129000)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Genentech, Inc. (SSF)</td>
<td class="formItem"></td>
<td class="formItem">080129000</td>
<td class="formItem">API MANUFACTURE(50242-080, 50242-082), ANALYSIS(50242-080, 50242-082)</td>
</tr>
</table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Roche Singapore Technical Operations Pte. Ltd.</td>
<td class="formItem"></td>
<td class="formItem">937189173</td>
<td class="formItem">API MANUFACTURE(50242-080, 50242-082), ANALYSIS(50242-080, 50242-082)</td>
</tr>
</table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Genentech, Inc. (Hillsboro)</td>
<td class="formItem"></td>
<td class="formItem">833220176</td>
<td class="formItem">LABEL(50242-080, 50242-082), PACK(50242-080, 50242-082)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 2/2015<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>1ec9a553-f2bc-4e05-9586-896c829a187c</div>
<div>Set id: de4e66cc-ca05-4dc9-8262-e00e9b41c36d</div>
<div>Version: 9</div>
<div>Effective Time: 20150220</div>
</div>
</div> <div class="DistributorName">Genentech, Inc.</div></p>
</body></html>
